Egfr binding proteins and methods of use

ABSTRACT

Provided herein are EGFR binding proteins and EGFR targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to EGFR. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such EGFR binding proteins, EGFR targeting trispecific proteins. Also disclosed are methods of using the disclosed EGFR binding proteins, EGFR targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.

CROSS-REFERENCE

This application claims the benefit of U.S. Provisional Application Nos. 62/734,892 filed on Sep. 21, 2018 and 62/734,908 filed on Sep. 21, 2018, each of which is incorporated by reference herein in its entirety.

BACKGROUND OF THE INVENTION

The selective destruction of an individual cell or a specific cell type is often desirable in a variety of clinical settings. For example, it is a primary goal of cancer therapy to specifically destroy tumor cells, while leaving healthy cells and tissues intact and undamaged. One such method is by inducing an immune response against the tumor, to make immune effector cells such as natural killer (NK) cells or cytotoxic T lymphocytes (CTLs) attack and destroy tumor cells.

Epidermal growth factor receptor (EGFR) has been causally implicated in human malignancy. Abnormal activity of the Her family of receptors is involved with breast cancer. EGFR, Her-3, and Her-4 are frequently expressed in ovarian granulosa cell tumors (Leibl, S. et al., Gynecol Oncol 101:18-23 (2005). In particular, increased expression of EGFR has been observed in breast, bladder, lung, head, neck and stomach cancer as well as glioblastomas.

Increased EGFR receptor expression may be associated with increased production of a EGFR ligand, transforming growth factor alpha (TGF-α), by the same tumor cells resulting in receptor activation by an autocrine stimulatory pathway.

Cetuximab (Erbitux™), an anti-EGFR antibody, has been associated with potentially life threatening infusion reactions (Thomas, M., Clin J Oncol Nurs. 9(3):332-8 (2005)). Gefitinib (Iressa™) and erlotinib (Tarceva™), both EGFR specific small molecule inhibitors, are associated with a risk of interstitial lung disease (Sandler A, Oncology 20(5 Suppl 2):35-40 (2006)). Individual patients may be predisposed to particular types of complications that affect the choice of drug treatment. There is a need for a greater choice of treatment options which allows physicians to select the therapeutic with the best side effect profile for an individual patient. The present disclosure provides novel polypeptides and protein therapeutics useful in methods of treatment, particularly for treatment of conditions associated with abnormal expression of EGFR.

SUMMARY OF THE INVENTION

One embodiment provides an EGFR binding trispecific protein, wherein said protein comprises (a) a first domain (A) which specifically binds to human CD3; (b) a second domain (B) which is a half-life extension domain; and (c) a third domain (C) which specifically binds to EGFR, wherein the domains are linked in the order H2N-(A)-(B)—(C)—COOH, H2N-(A)-(C)—(B)—COOH, H2N—(B)-(A)-(C)—COOH, H2N—(B)—(C)-(A)-COOH, H2N—(C)—(B)-(A)-COOH, or H2N—(C)-(A)-(B)—COOH, or by linkers L1 and L2 in the following order H2N-(A)-L1-(B)-L2-(C)—COOH, H2N-(A)-L1-(C)-L2-(B)—COOH, H2N—(B)-L1-(A)-L2-(C)—COOH, H2N—(B)-L1-(C)-L2-(A)-COOH, H2N—(C)-L1-(B)-L2-(A)-COOH, or H2N—(C)-L1-(A)-L2-(B)—COOH. In some embodiments, said first domain comprises a variable light domain and variable heavy domain each of which is capable of specifically binding to human CD3. In some embodiments, said first, second, and third domain independently comprise humanized or human sequences. In some embodiments, said second domain binds albumin. In some embodiments, said second domain comprises a scFv, a variable heavy domain (VH), a variable light domain (VL), a peptide, a ligand, or a small molecule. In some embodiments, said third domain comprises a VHH domain, a scFv, a VH domain, a VL domain, a non-Ig domain, a ligand, a knottin, or a small molecule entity that specifically binds to EGFR. In some embodiments, said third domain comprises the VHH domain. In some embodiments, said third domain comprises a complementarity determining region (CDR1) comprising a sequence that is at least about 75% identical to a sequence selected from the group consisting of: SEQ ID Nos. 50-98. In some embodiments, said third domain comprises a complementarity determining region (CDR2) comprising a sequence that is at least about 75% identical to a sequence selected from the group consisting of: SEQ ID Nos. 99-147. In some embodiments, said third domain comprises a complementarity determining region (CDR3) comprising a sequence that is at least about 75% identical to a sequence selected from the group consisting of: SEQ ID Nos. 148-196. In some embodiments, said third domain comprises a complementarity determining region (CDR1) comprising a sequence identical to or having one or more amino acid substitutions relative to a sequence selected from the group consisting of: SEQ ID Nos. 50-98. In some embodiments, said third domain comprises a complementarity determining region (CDR2) comprising a sequence identical to or having one or more amino acid substitutions relative to a sequence selected from the group consisting of: SEQ ID Nos. 99-147. In some embodiments, said third domain comprises a complementarity determining region (CDR3) comprising a sequence identical to or having one or more amino acid substitutions relative to a sequence selected from the group consisting of: SEQ ID Nos. 148-196. In some embodiments, said third domain comprises a complementarity determining region (CDR1) comprising a sequence that is selected from the group consisting of: SEQ ID Nos. 50-98. In some embodiments, said third domain comprises a complementarity determining region (CDR2) comprising a sequence that is selected from the group consisting of: SEQ ID Nos. 99-147. In some embodiments, said third domain comprises a complementarity determining region (CDR3) comprising a sequence that is selected from the group consisting of: SEQ ID Nos. 148-196. In some embodiments, said third domain comprises the following formula:

f1-r1-f2-r2-f3-r3-f4

wherein, r1 is identical to or comprises one or more amino acid residue substitutions relative to a sequence selected from the group consisting of SEQ ID Nos. 50-98; r2 is identical to or comprises one or more amino acid residue substitutions relative to a sequence selected from the group consisting of SEQ ID Nos. 99-147; and r3 is identical to or comprises one or more amino acid residue substitutions relative to a sequence selected from the group consisting of SEQ ID Nos. 148-196; and wherein f1, f2, f3 and f4 are framework residues. In some embodiments, said third domain comprises a sequence that is at least about 75% identical to a sequence selected from the group consisting of SEQ ID Nos. 1-49. In some embodiments, said third domain comprises a sequence selected from the group consisting of SEQ ID Nos. 1-49. In some embodiments, said third-domain is the VHH domain, and wherein the VHH domain comprises the humanized sequence. In some embodiments, said linkers L1 and L2 are each independently selected from (GS)n (SEQ ID NO: 197), (GGS)n (SEQ ID NO: 198), (GGGS)n (SEQ ID NO: 199), (GGSG)n (SEQ ID NO: 200), (GGSGG)n (SEQ ID NO: 201), (GGGGS)n (SEQ ID NO: 202), (GGGGG)n, or (GGG)n, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, said linkers L1 and L2 are each independently (GGGGSGGGGSGGGGS) (SEQ ID No. 314), (GGGGSGGGGSGGGGSGGGGS) (SEQ ID No. 315), or (GGGGSGGGS) (SEQ ID No. 246). In some embodiments, said domains are linked in the order H2N-(A)-(B)—(C)—COOH or H2N—(C)—(B)-(A)-COOH, H₂N-(A)-L1-(B)-L2-(C)—COOH, H₂N—(C)-L1-(B)-L2-(A)-COOH In some embodiments, said trispecific protein is less than about 80 kDa. In some embodiments, said trispecific protein is about 50 to about 75 kDa. In some embodiments, said trispecific protein is less than about 60 kDa. In some embodiments, said trispecific protein has an elimination half-time of at least about 50 hours. In some embodiments, said trispecific protein has an elimination half-time of at least about 100 hours. In some embodiments, said trispecific protein has increased tissue penetration as compared to an IgG to the same EGFR. In some embodiments, said second domain (B) binds a bulk serum protein. In some embodiments, said second domain (B) comprises a single domain antibody, a VHH domain, a scFv, a VH domain, a VL domain, a Fab, a Fab′, a non-Ig domain, a ligand, a knottin, or a small molecule entity that specifically binds to the bulk serum protein. In some embodiments, said second domain (B) comprises the single domain antibody that specifically binds to the bulk serum protein. In some embodiments, said bulk serum protein comprises albumin, transferrin, IgG1, IgG2, IgG4, IgG3, IgA monomer, Factor XIII, Fibrinogen, IgE, pentameric IgM, or Igκ free light chain. In some embodiments, said bulk serum protein comprises the albumin. In some embodiments, said second domain (B) comprises a sequence that is at least about 75% identical to a sequence selected from the group consisting of SEQ ID Nos. 205-214. In some embodiments, said second domain (B) comprises a sequence that is at least about 75% identical to SEQ ID No. 210. In some embodiments, said first domain (A) comprises a single domain antibody, a VHH domain, a scFv, a VH domain, a VL domain, a Fab, a Fab′, a non-Ig domain, a ligand, a knottin, or a small molecule entity that specifically binds to CD3. In some embodiments, said first domain (A) comprises a sequence that is at least about 75% identical to a sequence selected from the group consisting of SEQ ID Nos. 229-245. In some embodiments, said first domain (A) comprises a sequence that is at least 75% identical to SEQ ID No. 229.

One embodiment provides an EGFR binding protein comprising the following formula:

f1-r1-f2-r2-f3-r3-f4

wherein, r1 is a complementarity determining region 1 (CDR1) and is identical to or comprises one or more amino acid residue substitutions relative to a sequence selected from the group consisting of SEQ ID Nos. 50-98; r2 is a CDR2 and is identical to or comprises one or more amino acid residue substitutions relative to a sequence selected from the group consisting of SEQ ID Nos. 99-147; and r3 is a CDR3 and identical to or comprises one or more amino acid residue substitutions relative to a sequence selected from the group consisting of SEQ ID Nos. 148-196; and wherein f1, f2, f3 and f4 are framework residues. In some embodiments, the EGFR binding protein comprises a sequence that is at least about 75% identical to a sequence selected from the group consisting of SEQ ID Nos. 1-49.

One embodiment provides a pharmaceutical composition comprising (i) the EGFR binding trispecific protein according to any one of the preceding embodiments and (ii) a pharmaceutically acceptable carrier. One embodiment provides a process for the production of an EGFR binding trispecific protein according to any one of the preceding embodiments, said process comprising culturing a host transformed or transfected with a vector comprising a nucleic acid sequence encoding an EGFR binding trispecific protein according to any one of the preceding embodiments under conditions allowing the expression of the EGFR binding trispecific protein and recovering and purifying the produced protein from the culture. One embodiment provides a process for the production of an EGFR binding protein according to this disclosure, said process comprising culturing a host transformed or transfected with a vector comprising a nucleic acid sequence encoding an EGFR binding protein according to this disclosure under conditions allowing the expression of the EGFR binding protein and recovering and purifying the produced protein from the culture.

One embodiment provides a method for the treatment or amelioration of a proliferative disease, or a tumorous disease, comprising administration of an EGFR binding trispecific protein, an EGFR binding protein, or a pharmaceutical composition according to any one of the preceding embodiments, to a subject in need thereof. In some embodiments, said subject is human. In some embodiments, said method further comprises administration of an agent in combination with an EGFR binding trispecific protein, an EGFR binding protein, or a pharmaceutical composition according to any one of the preceding embodiments. In some embodiments are provided a method wherein the EGFR binding protein or the EGFR binding trispecific protein selectively binds to tumor cells expressing EGFR. In some embodiments are provided a method wherein said EGFR binding trispecific protein mediates T cell killing of tumor cells expressing EGFR. In some embodiments are provided a method wherein said tumorous disease comprises a solid tumor disease. In some embodiments are provided a method wherein the solid tumor disease comprises lung cancer, gastric cancer, ovarian cancer, or triple negative breast cancer. In some embodiments are provided a method wherein the solid tumor disease is metastatic.

One embodiment provides a method for the treatment or amelioration of a proliferative disease, or a tumorous disease, comprising administration of an EGFR binding trispecific protein comprising an EGFR binding domain comprising a sequence selected from the group consisting of SEQ ID Nos. 1-49. In some embodiments, the EGFR binding protein or the EGFR binding trispecific protein selectively binds to tumor cells expressing EGFR. In some embodiments, said EGFR binding trispecific protein directs T cell killing of tumor cells expressing EGFR. In some embodiments, said tumorous disease comprises a solid tumor disease. In some embodiments, said solid tumor disease comprises lung cancer, gastric cancer, ovarian cancer, or triple negative breast cancer. In some embodiments, said solid tumor disease is metastatic. In some embodiments, the method comprises administering the EGFR binding protein or the EGFR binding trispecific protein at a dose of up to 10 mg/kg. In some embodiments, the EGFR binding protein or the EGFR binding trispecific protein is administered once a week. In some embodiments, the EGFR binding protein or the EGFR binding trispecific protein is administered twice per week. In some embodiments, the EGFR binding protein or the EGFR binding trispecific protein is administered every other week. In some embodiments, the EGFR binding protein or the EGFR binding trispecific protein is administered every three weeks.

One embodiment provides an EGFR binding trispecific protein, comprising a sequence selected from the group consisting of SEQ ID Nos. 1-49. In some embodiments, said third domain comprises a CDR1 comprising a sequence as set forth in any one of SEQ ID Nos. 50-98. In some embodiments, said third domain comprises a CDR2 comprising a sequence as set forth in any one of SEQ ID Nos. 99-147. In some embodiments, said third domain comprises a CDR3 comprising a sequence as set forth in any one of SEQ ID Nos. 148-196.

One embodiment provides an EGFR binding trispecific protein comprising a sequence selected from a group consisting of SEQ ID Nos. 319-367.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

FIG. 1 illustrates the various domains of an exemplary EGFR targeting trispecific protein of this disclosure.

FIG. 2 illustrates results of a T cell dependent cellular cytotoxicity (TDCC) assay on HCT116 cells, using exemplary EGFR targeting trispecific proteins containing EGFR binding domains of this disclosure, EL1, EL4, EL16, EL18, EL38, and EL44.

FIG. 3 illustrates results of a TDCC assay on HCT116 cells, using exemplary EGFR targeting trispecific proteins containing exemplary EGFR binding domains of this disclosure EL60, EL64, EL77, EL104, and EL 113.

FIG. 4 illustrates results of a TDCC assay on HCT116 cells, using exemplary EGFR targeting trispecific proteins containing exemplary humanized EGFR binding domains of this disclosure EH1, EH4, EH16, EH18, EH38, and EH44.

FIG. 5 illustrates results of a TDCC assay on HCT116 cells, using exemplary EGFR targeting trispecific proteins containing exemplary humanized EGFR binding domains of this disclosure EH60, EH64, EH77, EH104, EH113, and a control trispecific protein aGFP TriTAC™.

DETAILED DESCRIPTION OF THE INVENTION

Described herein are trispecific proteins that target EGFR, pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such proteins thereof. Also provided are methods of using the disclosed EGFR targeting trispecific proteins in the prevention, and/or treatment of diseases, conditions and disorders. The EGFR targeting trispecific proteins are capable of specifically binding to EGFR as well as CD3 and have a half-life extension domain, such as a domain binding to human albumin (ALB). FIG. 1 depicts one non-limiting example of a trispecific EGFR-binding protein.

Certain Definitions

The terminology used herein is for the purpose of describing particular cases only and is not intended to be limiting. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms “including”, “includes”, “having”, “has”, “with”, or variants thereof are used in either the detailed description and/or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising.”

The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, e.g., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the given value. Where particular values are described in the application and claims, unless otherwise stated the term “about” should be assumed to mean an acceptable error range for the particular value.

The terms “individual,” “patient,” or “subject” are used interchangeably. None of the terms require or are limited to situation characterized by the supervision (e.g. constant or intermittent) of a health care worker (e.g. a doctor, a registered nurse, a nurse practitioner, a physician's assistant, an orderly, or a hospice worker).

An “antibody” typically refers to a Y-shaped tetrameric protein comprising two heavy (H) and two light (L) polypeptide chains held together by covalent disulfide bonds and non-covalent interactions. Human light chains comprise a variable domain (VL) and a constant domain (CL) wherein the constant domain may be readily classified as kappa or lambda based on amino acid sequence and gene loci. Each heavy chain comprises one variable domain (VH) and a constant region, which in the case of IgG, IgA, and IgD, comprises three domains termed CH1, CH2, and CH3 (IgM and IgE have a fourth domain, CH4). In IgG, IgA, and IgD classes the CH1 and CH2 domains are separated by a flexible hinge region, which is a proline and cysteine rich segment of variable length (generally from about 10 to about 60 amino acids in IgG). The variable domains in both the light and heavy chains are joined to the constant domains by a “J” region of about 12 or more amino acids and the heavy chain also has a “D” region of about 10 additional amino acids. Each class of antibody further comprises inter-chain and intra-chain disulfide bonds formed by paired cysteine residues. There are two types of native disulfide bridges or bonds in immunoglobulin molecules: interchain and intrachain disulfide bonds. The location and number of interchain disulfide bonds vary according to the immunoglobulin class and species. Interchain disulfide bonds are located on the surface of the immunoglobulin, are accessible to solvent and are usually relatively easily reduced. In the human IgG1 isotype there are four interchain disulfide bonds, one from each heavy chain to the light chain and two between the heavy chains. The interchain disulfide bonds are not required for chain association. As is well known the cysteine rich IgG1 hinge region of the heavy chain has generally been held to consist of three parts: an upper hinge, a core hinge, and a lower hinge. Those skilled in the art will appreciate that that the IgG1 hinge region contain the cysteines in the heavy chain that comprise the interchain disulfide bonds (two heavy/heavy, two heavy/light), which provide structural flexibility that facilitates Fab movements. The interchain disulfide bond between the light and heavy chain of IgG1 are formed between C214 of the kappa or lambda light chain and C220 in the upper hinge region of the heavy chain. The interchain disulfide bonds between the heavy chains are at positions C226 and C229 (all numbered per the EU index according to Kabat, et al., infra.)

As used herein the term “antibody” includes polyclonal antibodies, multiclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized and primatized antibodies, CDR grafted antibodies, human antibodies, recombinantly produced antibodies, intrabodies, multi specific antibodies, bispecific antibodies, monovalent antibodies, multivalent antibodies, anti-idiotypic antibodies, synthetic antibodies, including muteins and variants thereof, immunospecific antibody fragments such as Fd, Fab, F(ab′)2, F(ab′) fragments, single-chain fragments (e.g., ScFv and ScFvFc), disulfide-linked Fvs (sdFv), a Fd fragment consisting of the VH and CH1 domains, linear antibodies, single domain antibodies such as sdAb (VH, VL, or VHH domains); and derivatives thereof including Fc fusions and other modifications, and any other immunoreactive molecule so long as it comprises a domain having a binding site for preferential association or binding with a EGFR protein. Moreover, unless dictated otherwise by contextual constraints the term further comprises all classes of antibodies (i.e. IgA, IgD, IgE, IgG, and IgM) and all subclasses (i.e., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2). Heavy-chain constant domains that correspond to the different classes of antibodies are typically denoted by the corresponding lower case Greek letter alpha, delta, epsilon, gamma, and mu, respectively. Light chains of the antibodies from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (kappa) and lambda (lambda), based on the amino acid sequences of their constant domains.

In some embodiments, the EGFR binding domain of the EGFR targeting trispecific proteins of this disclosure comprise a heavy chain only antibody, such as a VH or a VHH domain. In some embodiments, the EGFR binding domain of the EGFR targeting trispecific proteins of this disclosure comprise a heavy chain only single domain antibody. In some cases, the EGFR binding proteins comprise a heavy chain only antibody that is an engineered human VH domain. In some examples, the engineered human VH domain is produced by panning of phage display libraries. In some embodiments, the EGFR binding domain of the EGFR targeting trispecific proteins of this disclosure comprise a VHH. The term “VHH,” as used herein, refers to single chain antibody binding domain devoid of light chain. In some cases, a VHH is derived from an antibody of the type that can be found in Camelidae or cartilaginous fish which are naturally devoid of light chains or to a synthetic and non-immunized VHH which can be constructed accordingly. Each heavy chain comprises a variable region encoded by V-, D- and J exons. A VHH, in some cases, is a natural VHH, such as a Camelid-derived VHH, or a recombinant protein comprising a heavy chain variable domain. In some embodiments, the VHH is derived from a species selected from the group consisting of camels, llamas, vicugnas, guanacos, and cartilaginous fish (such as, but not limited to, sharks). In another embodiment, the VHH is derived from an alpaca (such as, but not limited to, a Huacaya Alpaca or a Suri alpaca).

As used herein, “Variable region” or “variable domain” refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions both in the light-chain (VL) and the heavy-chain (VH) variable domains. The more highly conserved portions of variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise four FR regions, largely adopting a β-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the β sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity. ScFv fragments (for single chain fragment variable), which in some cases are obtained by genetic engineering, associates in a single polypeptide chain, the VH and the VL region of an antibody, separated by a peptide linker.

In some embodiments of this disclosure, the EGFR binding domain, such as the EGFR binding domain of the EGFR targeting trispecific proteins comprise a single domain antibody, such as heavy chain only antibodies, such as VH or VHH domains, that comprise three CDRs. Such heavy chain only antibodies, in some embodiments, bind EGFR as a monomer with no dependency on dimerisation with a VL (light chain variable) region for optimal binding affinity. In some embodiments of this disclosure, the CD3 binding domain of the EGFR targeting trispecific proteins comprises an scFv. In some embodiments of this disclosure, the albumin binding domain of the EGFR targeting trispecific proteins comprise a heavy chain only antibody, such as a single domain antibody comprising a VH domain or a VHH domain, that comprises three CDRs.

The assignment of amino acids to each domain, framework region and CDR is, in some embodiments, in accordance with one of the numbering schemes provided by Kabat et al. (1991) Sequences of Proteins of Immunological Interest (5th Ed.), US Dept. of Health and Human Services, PHS, NIH, NIH Publication no. 91-3242; Chothia et al., 1987, PMID: 3681981; Chothia et al., 1989, PMID: 2687698; MacCallum et al., 1996, PMID: 8876650; or Dubel, Ed. (2007) Handbook of Therapeutic Antibodies, 3rd Ed., Wily-VCH Verlag GmbH and Co or AbM (Oxford Molecular/MSI Pharmacopia) unless otherwise noted. It is not intended that CDRs of the present disclosure necessarily correspond to the Kabat numbering convention.

“Variable domain residue numbering as in Kabat” or “amino acid position numbering as in Kabat,” and variations thereof, refers to the numbering system used for heavy chain variable domains or light chain variable domains of the compilation of antibodies in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991). Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a FR or CDR of the variable domain. For example, a heavy chain variable domain may include a single amino acid insert (residue 52a according to Kabat) after residue 52 of H2 and inserted residues (e.g., residues 82a, 82b, and 82c, etc according to Kabat) after heavy chain FR residue 82. The Kabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a “standard” Kabat numbered sequence.

The term “Framework” or “FR” residues (or regions) refer to variable domain residues other than the CDR or hypervariable region residues as herein defined. A “human consensus framework” is a framework which represents the most commonly occurring amino acid residue in a selection of human immunoglobulin VL or VH framework sequences.

The term “epitope,” as used herein, refers to an antigenic determinant that interacts with a specific antigen binding site in the variable region of an antibody molecule known as a paratope. A single antigen may have more than one epitope. Thus, different antibodies may bind to different areas on an antigen and may have different biological effects. Epitopes may be either conformational or linear. A conformational epitope is produced by spatially juxtaposed amino acids from different segments of the linear polypeptide chain. A linear epitope is one produced by adjacent amino acid residues in a polypeptide chain. In certain circumstance, an epitope may include moieties of saccharides, phosphoryl groups, or sulfonyl groups on the antigen.

As used herein, the term “Percent (%) amino acid sequence identity” with respect to a sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer softwares such as EMBOSS MATCHER, EMBOSS WATER, EMBOSS STRETCHER, EMBOSS NEEDLE, EMBOSS LALIGN, BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

As used herein, “elimination half-time” is used in its ordinary sense, as is described in Goodman and Gillman's The Pharmaceutical Basis of Therapeutics 21-25 (Alfred Goodman Gilman, Louis S. Goodman, and Alfred Gilman, eds., 6th ed. 1980). Briefly, the term is meant to encompass a quantitative measure of the time course of drug elimination. The elimination of most drugs is exponential (i.e., follows first-order kinetics), since drug concentrations usually do not approach those required for saturation of the elimination process. The rate of an exponential process may be expressed by its rate constant, k, which expresses the fractional change per unit of time, or by its half-time, t½ the time required for 50% completion of the process. The units of these two constants are time—1 and time, respectively. A first-order rate constant and the half-time of the reaction are simply related (k×t½=0.693) and may be interchanged accordingly. Since first-order elimination kinetics dictates that a constant fraction of drug is lost per unit time, a plot of the log of drug concentration versus time is linear at all times following the initial distribution phase (i.e. after drug absorption and distribution are complete). The half-time for drug elimination can be accurately determined from such a graph.

As used herein, the term “binding affinity” refers to the affinity of the proteins described in the disclosure to their binding targets, and is expressed numerically using “Kd” values. If two or more proteins are indicated to have comparable binding affinities towards their binding targets, then the Kd values for binding of the respective proteins towards their binding targets, are within +2-fold of each other. If two or more proteins are indicated to have comparable binding affinities towards single binding target, then the Kd values for binding of the respective proteins towards said single binding target, are within ±2-fold of each other. If a protein is indicated to bind two or more targets with comparable binding affinities, then the Kd values for binding of said protein to the two or more targets are within ±2-fold of each other. In general, a higher Kd value corresponds to a weaker binding. In some embodiments, the “Kd” is measured by a radiolabeled antigen binding assay (RIA) or surface plasmon resonance assays using a BIAcore™-2000 or a BIAcore™-3000 (BIAcore, Inc., Piscataway, N.J.). In certain embodiments, an “on-rate” or “rate of association” or “association rate” or “kon” and an “off-rate” or “rate of dissociation” or “dissociation rate” or “koff” are also determined with the surface plasmon resonance technique using a BIAcore™-2000 or a BIAcore™-3000 (BIAcore, Inc., Piscataway, N.J.). In additional embodiments, the “Kd”, “kon”, and “koff” are measured using the OCTET® Systems (Pall Life Sciences). In an exemplary method for measuring binding affinity using the OCTET® Systems, the ligand, e.g., biotinylated human, mouse or cynomolgus EGFR, is immobilized on the OCTET® streptavidin capillary sensor tip surface which streptavidin tips are then activated according to manufacturer's instructions using about 20-50 μg/ml human, mouse or cynomolgus EGFR protein. A solution of PBS/Casein is also introduced as a blocking agent. For association kinetic measurements, EGFR binding protein variants are introduced at a concentration ranging from about 10 ng/mL to about 100 μg/mL, about 50 ng/mL to about 5 μg/mL, or about 2 ng/mL to about 20 μg/mL. In some embodiments, the EGFR binding single domain proteins are used at a concentration ranging from about 2 ng/mL to about 20 μg/mL. Complete dissociation is observed in case of the negative control, assay buffer without the binding proteins. The kinetic parameters of the binding reactions are then determined using an appropriate tool, e.g., ForteBio software.

As used herein, in some embodiments, “treatment” or “treating” or “treated” refers to therapeutic treatment wherein the object is to slow (lessen) an undesired physiological condition, disorder or disease, or to obtain beneficial or desired clinical results. For the purposes described herein, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of the condition, disorder or disease; stabilization (i.e., not worsening) of the state of the condition, disorder or disease; delay in onset or slowing of the progression of the condition, disorder or disease; amelioration of the condition, disorder or disease state; and remission (whether partial or total), whether detectable or undetectable, or enhancement or improvement of the condition, disorder or disease. Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment. In other embodiments, “treatment” or “treating” or “treated” refers to prophylactic measures, wherein the object is to delay onset of or reduce severity of an undesired physiological condition, disorder or disease, such as, for example is a person who is predisposed to a disease (e.g., an individual who carries a genetic marker for a disease such as breast cancer).

One embodiment provides an EGFR binding protein (also referred to herein as an EGFR binding domain, such as the EGFR binding domain of an EGFR trispecific antibody of this disclosure) that comprises a single domain antibody, comprising a CDR1 sequence comprising a sequence selected from the group consisting of SEQ ID Nos. 50-98, a CDR2 sequence comprising a sequence selected from the group consisting of SEQ ID Nos. 99-147, and a CDR3 sequence comprising a sequence selected from the group consisting of SEQ ID Nos. 148-196. It is contemplated that in some embodiments the EGFR binding protein of this disclosure is fairly small and no more than 25 kD, no more than 20 kDa, no more than 15 kDa, or no more than 10 kDa in some embodiments. In certain instances, the EGFR binding is 5 kDa or less if it is a peptide or a small molecule entity.

In some embodiments are provided EGFR targeting trispecific proteins (also referred to herein as EGFR targeting trispecific proteins, EGFR trispecific proteins, or EGFR TriTAC™), wherein the EGFR targeting trispecific proteins comprise a domain (A) which specifically binds to CD3, a domain (B) which specifically binds to a bulk serum protein, such as human serum albumin protein (ALB or HSA), and a domain (C) which specifically binds to EGFR (such as an EGFR binding single domain antibody as described herein). The three domains in EGFR targeting trispecific proteins are arranged in any order. Thus, it is contemplated that the domain order of the EGFR targeting trispecific proteins are:

H₂N-(A)-(B)—(C)—COOH,

H₂N-(A)-(C)—(B)—COOH,

H₂N—(B)-(A)-(C)—COOH,

H₂N—(B)—(C)-(A)-COOH,

H₂N—(C)—(B)-(A)-COOH, or

H₂N—(C)-(A)-(B)—COOH.

In some embodiments, the EGFR targeting trispecific proteins have a domain order of H₂N-(A)-(B)—(C)—COOH. In some embodiments, the EGFR targeting trispecific proteins have a domain order of H₂N-(A)-(C)—(B)—COOH. In some embodiments, the EGFR targeting trispecific proteins have a domain order of H₂N—(B)-(A)-(C)—COOH. In some embodiments, the EGFR targeting trispecific proteins have a domain order of H₂N—(B)—(C)-(A)-COOH. In some embodiments, the EGFR targeting trispecific proteins have a domain order of H₂N—(C)—(B)-(A)-COOH. In some embodiments, the EGFR targeting trispecific proteins have a domain order of H₂N—(C)-(A)-(B)—COOH.

In some embodiments, the EGFR targeting trispecific proteins have the HSA binding domain as the middle domain, such that the domain order is H₂N-(A)-(B)—(C)—COOH or H₂N—(C)—(B)-(A)-COOH. It is contemplated that in such embodiments where the bulk serum protein binding domain as the middle domain, the CD3 and EGFR binding domains are afforded additional flexibility to bind to their respective targets.

In some embodiments, the EGFR targeting trispecific proteins described herein comprise an EGFR binding domain, such as a polypeptide comprising a sequence selected from SEQ ID Nos. 1-49 and subsequences thereof. In some embodiments, the trispecific antigen binding protein comprises an EGFR binding domain, a polypeptide comprising a sequence that has at least 70%-95% or more homology to a sequence selected from SEQ ID Nos. 1-49. In some embodiments, the trispecific antigen binding protein comprises an EGFR binding domain, such as a polypeptide comprising a sequence that has at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, or more homology to a sequence selected from SEQ ID Nos. 1-49.

In some embodiments, the EGFR targeting trispecific proteins described herein comprise an EGFR binding domain, such as a polypeptide comprising a sequence selected from SEQ ID Nos. 1-49 and subsequences thereof. In some embodiments, the trispecific antigen binding protein comprises an EGFR binding domain, a polypeptide comprising a sequence that has at least 70%-95% or more identity to a sequence selected from SEQ ID Nos. 1-49. In some embodiments, the trispecific antigen binding protein comprises an EGFR binding domain, such as a polypeptide comprising a sequence that has at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, or more identity to a sequence selected from SEQ ID Nos. 1-49.

The EGFR targeting trispecific proteins described herein are designed to allow specific targeting of cells expressing EGFR by recruiting cytotoxic T cells. This improves efficacy compared to ADCC (antibody dependent cell-mediated cytotoxicity), which is using full length antibodies directed to a sole antigen and is not capable of directly recruiting cytotoxic T cells. In contrast, by engaging CD3 molecules expressed specifically on these cells, the EGFR targeting trispecific proteins can crosslink cytotoxic T cells with cells expressing EGFR in a highly specific fashion, thereby directing the cytotoxic potential of the T cell towards the target cell. The EGFR targeting trispecific proteins described herein engage cytotoxic T cells via binding to the surface-expressed CD3 proteins, which form part of the T-cell receptor (TCR). Simultaneous binding of several EGFR trispecific antigen-binding protein to CD3 and to EGFR expressed on the surface of particular cells causes T cell activation and mediates the subsequent lysis of the particular EGFR expressing cell. Thus, EGFR targeting trispecific proteins, in some embodiments, display strong, specific and efficient target cell killing. In some embodiments, the EGFR targeting trispecific proteins described herein stimulate target cell killing by cytotoxic T cells to eliminate pathogenic cells (e.g., tumor cells expressing EGFR). In some of such embodiments, cells are eliminated selectively, thereby reducing the potential for toxic side effects.

The EGFR targeting trispecific proteins described herein confer further therapeutic advantages over traditional monoclonal antibodies and other smaller bispecific molecules. Generally, the effectiveness of recombinant protein pharmaceuticals depends heavily on the intrinsic pharmacokinetics of the protein itself. One such benefit here is that the EGFR targeting trispecific proteins described herein have extended pharmacokinetic elimination half-time due to having a half-life extension domain such as a domain specific to HSA. In this respect, the EGFR targeting trispecific proteins described herein have an extended serum elimination half-time of about two, three, about five, about seven, about 10, about 12, or about 14 days in some embodiments. This contrasts to other binding proteins such as BiTE or DART molecules which have relatively much shorter elimination half-times. For example, the BiTE CD19×CD3 bispecific scFv-scFv fusion molecule requires continuous intravenous infusion (i.v.) drug delivery due to its short elimination half-time. The longer intrinsic half-times of the EGFR targeting trispecific proteins solve this issue thereby allowing for increased therapeutic potential such as low-dose pharmaceutical formulations, decreased periodic administration and/or novel pharmaceutical compositions.

The EGFR targeting trispecific proteins described herein also have an optimal size for enhanced tissue penetration and tissue distribution. Larger sizes limit or prevent penetration or distribution of the protein in the target tissues. The EGFR targeting trispecific proteins described herein avoid this by having a small size that allows enhanced tissue penetration and distribution. Accordingly, the EGFR targeting trispecific proteins described herein, in some embodiments have a size of about 50 kD to about 80 kD, about 50 kD to about 75 kD, about 50 kD to about 70 kD, or about 50 kD to about 65 kD. Thus, the size of the EGFR targeting trispecific proteins is advantageous over IgG antibodies which are about 150 kD and the BiTE and DART diabody molecules which are about 55 kD but are not half-life extended and therefore cleared quickly through the kidney.

In further embodiments, the EGFR targeting trispecific proteins described herein have an optimal size for enhanced tissue penetration and distribution. In these embodiments, the EGFR targeting trispecific proteins are constructed to be as small as possible, while retaining specificity toward its targets. Accordingly, in these embodiments, the EGFR targeting trispecific proteins described herein have a size of about 20 kD to about 40 kD or about 25 kD to about 35 kD to about 40 kD, to about 45 kD, to about 50 kD, to about 55 kD, to about 60 kD, to about 65 kD. In some embodiments, the EGFR targeting trispecific proteins described herein have a size of about 50 kD, 49, kD, 48 kD, 47 kD, 46 kD, 45 kD, 44 kD, 43 kD, 42 kD, 41 kD, 40 kD, about 39 kD, about 38 kD, about 37 kD, about 36 kD, about 35 kD, about 34 kD, about 33 kD, about 32 kD, about 31 kD, about 30 kD, about 29 kD, about 28 kD, about 27 kD, about 26 kD, about 25 kD, about 24 kD, about 23 kD, about 22 kD, about 21 kD, or about 20 kD. An exemplary approach to the small size is through the use of single domain antibody (sdAb) fragments for each of the domains. For example, a particular EGFR trispecific antigen-binding protein has an anti-CD3 sdAb, anti-ALB sdAb and an sdAb for EGFR. This reduces the size of the exemplary EGFR trispecific antigen-binding protein to under 60 kD. Thus in some embodiments, the domains of the EGFR targeting trispecific proteins are all single domain antibody (sdAb) fragments.

In other embodiments, the EGFR targeting trispecific proteins described herein comprise small molecule entity (SME) binders for ALB and/or the EGFR. SME binders are small molecules averaging about 500 to 2000 Da in size and are attached to the EGFR targeting trispecific proteins by known methods, such as sortase ligation or conjugation. In these instances, one of the domains of EGFR trispecific antigen-binding protein is a sortase recognition sequence, e.g., LPETG (SEQ ID No. 313). To attach an SME binder to EGFR trispecific antigen-binding protein with a sortase recognition sequence, the protein is incubated with a sortase and a SME binder whereby the sortase attaches the SME binder to the recognition sequence. Known SME binders include, but are not limited to quinazolines (e.g., gefitinib, erlotinib). EGFR. In yet other embodiments, the domain which binds to EGFR of EGFR targeting trispecific proteins described herein comprise a knottin peptide for binding EGFR. Knottins are disufide-stabilized peptides with a cysteine knot scaffold and have average sizes about 3.5 kD. Knottins have been contemplated for binding to certain tumor molecules such as EGFR. In further embodiments, domain which binds to EGFR of EGFR targeting trispecific proteins described herein comprise a natural EGFR ligand.

Another feature of the EGFR targeting trispecific proteins described herein is that they are of a single-polypeptide design with flexible linkage of their domains. This allows for facile production and manufacturing of the EGFR targeting trispecific proteins as they can be encoded by single cDNA molecule to be easily incorporated into a vector. Further, because the EGFR targeting trispecific proteins described herein are a monomeric single polypeptide chain, there are no chain pairing issues or a requirement for dimerization. It is contemplated that the EGFR targeting trispecific proteins described herein have a reduced tendency to aggregate unlike other reported molecules such as bispecific proteins with Fc-gamma immunoglobulin domains.

In the EGFR targeting trispecific proteins described herein, the domains are linked by internal linkers L1 and L2, where L1 links the first and second domain of the EGFR targeting trispecific proteins and L2 links the second and third domains of the EGFR targeting trispecific proteins. Linkers L1 and L2 have an optimized length and/or amino acid composition. In some embodiments, linkers L1 and L2 are the same length and amino acid composition. In other embodiments, L1 and L2 are different. In certain embodiments, internal linkers L1 and/or L2 are “short,” i.e., consist of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acid residues. Thus, in certain instances, the internal linkers consist of about 12 or less amino acid residues. In the case of 0 amino acid residues, the internal linker is a peptide bond. In certain embodiments, internal linkers L1 and/or L2 are “long,” i.e., consist of 15, 20 or 25 amino acid residues. In some embodiments, these internal linkers consist of about 3 to about 15, for example 8, 9 or 10 contiguous amino acid residues. Regarding the amino acid composition of the internal linkers L1 and L2, peptides are selected with properties that confer flexibility to the EGFR targeting trispecific proteins, do not interfere with the binding domains as well as resist cleavage from proteases. For example, glycine and serine residues generally provide protease resistance. Examples of internal linkers suitable for linking the domains in the EGFR targeting trispecific proteins include but are not limited to but are not limited to (GS)_(n) (SEQ ID No. 197), (GGS)_(n) (SEQ ID No. 198), (GGGS)_(n) (SEQ ID No. 199), (GGSG)_(n) (SEQ ID No. 200), (GGSGG), (SEQ ID No. 201), (GGGGS)_(n) (SEQ ID No. 202), (GGGGG)_(n) (SEQ ID No. 203), or (GGG)_(n) (SEQ ID No. 204), wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment, the internal linkers L1 and/or L2 independently are (GGGGSGGGGSGGGGS) (SEQ ID No. 314), (GGGGSGGGGSGGGGSGGGGS) (SEQ ID No. 315), or (GGGGSGGGS) (SEQ ID No. 246).

CD3 Binding Domain

The specificity of the response of T cells is mediated by the recognition of antigen (displayed in context of a major histocompatibility complex, MHC) by the TCR. As part of the TCR, CD3 is a protein complex that includes a CD3γ (gamma) chain, a CD3δ (delta) chain, and two CD3ε (epsilon) chains which are present on the cell surface. CD3 associates with the α (alpha) and β (beta) chains of the TCR as well as CD3ζ (zeta) altogether to comprise the complete TCR. Clustering of CD3 on T cells, such as by immobilized anti-CD3 antibodies leads to T cell activation similar to the engagement of the T cell receptor but independent of its clone-typical specificity.

In one aspect, the EGFR targeting trispecific proteins described herein comprise a domain which specifically binds to CD3. In one aspect, the EGFR targeting trispecific proteins described herein comprise a domain which specifically binds to human CD3. In some embodiments, the EGFR targeting trispecific proteins described herein comprise a domain which specifically binds to CD3γ. In some embodiments, the EGFR targeting trispecific proteins described herein comprise a domain which specifically binds to CD3δ. In some embodiments, the EGFR targeting trispecific proteins described herein comprise a domain which specifically binds to CD3E.

In further embodiments, the EGFR targeting trispecific proteins described herein comprise a domain which specifically binds to the TCR. In certain instances, the EGFR targeting trispecific proteins described herein comprise a domain which specifically binds the a chain of the TCR. In certain instances, the EGFR targeting trispecific proteins described herein comprise a domain which specifically binds the R chain of the TCR.

In certain embodiments, the CD3 binding domain of the EGFR targeting trispecific proteins described herein exhibit not only potent CD3 binding affinities with human CD3, but show also excellent crossreactivity with the respective cynomolgus monkey CD3 proteins. In some instances, the CD3 binding domain of the EGFR targeting trispecific proteins are cross-reactive with CD3 from cynomolgus monkey. In certain instances, human:cynomolgous K_(D) ratios for CD3 are between 5 and 0.2.

In some embodiments, the CD3 binding domain of the EGFR trispecific antigen-binding protein can be any domain that binds to CD3 including but not limited to domains from a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody. In some instances, it is beneficial for the CD3 binding domain to be derived from the same species in which the EGFR trispecific antigen-binding protein will ultimately be used in. For example, for use in humans, it may be beneficial for the CD3 binding domain of the EGFR trispecific antigen-binding protein to comprise human or humanized residues from the antigen binding domain of an antibody or antibody fragment.

Thus, in one aspect, the antigen-binding domain comprises a humanized or human antibody or an antibody fragment, or a murine antibody or antibody fragment. In one embodiment, the humanized or human anti-CD3 binding domain comprises one or more (e.g., all three) light chain complementary determining region 1 (LC CDR1), light chain complementary determining region 2 (LC CDR2), and light chain complementary determining region 3 (LC CDR3) of a humanized or human anti-CD3 binding domain described herein, and/or one or more (e.g., all three) heavy chain complementary determining region 1 (HC CDR1), heavy chain complementary determining region 2 (HC CDR2), and heavy chain complementary determining region 3 (HC CDR3) of a humanized or human anti-CD3 binding domain described herein, e.g., a humanized or human anti-CD3 binding domain comprising one or more, e.g., all three, LC CDRs and one or more, e.g., all three, HC CDRs.

In some embodiments, the humanized or human anti-CD3 binding domain comprises a humanized or human light chain variable region specific to CD3 where the light chain variable region specific to CD3 comprises human or non-human light chain CDRs in a human light chain framework region. In certain instances, the light chain framework region is a λ (lamda) light chain framework. In other instances, the light chain framework region is a κ (kappa) light chain framework.

In some embodiments, the humanized or human anti-CD3 binding domain comprises a humanized or human heavy chain variable region specific to CD3 where the heavy chain variable region specific to CD3 comprises human or non-human heavy chain CDRs in a human heavy chain framework region.

In certain instances, the complementary determining regions of the heavy chain and/or the light chain are derived from known anti-CD3 antibodies, such as, for example, muromonab-CD3 (OKT3), otelixizumab (TRX4), teplizumab (MGA031), visilizumab (Nuvion), SP34, TR-66 or X35-3, VIT3, BMA030 (BW264/56), CLB-T3/3, CRIS7, YTH12.5, F111-409, CLB-T3.4.2, TR-66, WT32, SPv-T3b, 11D8, XIII-141, XIII-46, XIII-87, 12F6, T3/RW2-8C8, T3/RW2-4B6, OKT3D, M-T301, SMC2, F101.01, UCHT-1 and WT-31.

In one embodiment, the CD3 binding domain is a single chain variable fragment (scFv) comprising a light chain and a heavy chain of an amino acid sequence provided herein. As used herein, “single chain variable fragment” or “scFv” refers to an antibody fragment comprising a variable region of a light chain and at least one antibody fragment comprising a variable region of a heavy chain, wherein the light and heavy chain variable regions are contiguously linked via a short flexible polypeptide linker, and capable of being expressed as a single polypeptide chain, and wherein the scFv retains the specificity of the intact antibody from which it is derived. In an embodiment, the CD3 binding domain comprises: a light chain variable region comprising an amino acid sequence having at least one, two or three modifications (including insertion, deletion, or substitutions) but not more than 30, 20 or 10 modifications (including insertion, deletion, or substitutions) of an amino acid sequence of a light chain variable region provided herein, or a sequence with 95-99% identity with an amino acid sequence provided herein; a heavy chain variable region comprising an amino acid sequence having at least one, two or three modifications (including insertion, deletion, or substitutions) but not more than 30, 20 or 10 modifications (including insertion, deletion, or substitutions) of an amino acid sequence of a heavy chain variable region provided herein, or a sequence with 95-99% identity to an amino acid sequence provided herein, or a combination thereof. In some examples, the CD3 binding domain comprises a sequence selected from SEQ ID Nos. 229-245, or a sequence that is at least about 60%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identity to a sequence selected from SEQ ID Nos. 229-245. In some examples, the anti-CD3 binding domain comprises three heavy chain CDRs (HC CDR1, HC CDR2, and HC CDR3), and three light chain CDRs (LC CDR1, LC CDR2, and LC CDR3). The heavy chain CDR1(HC CDR1) of the CD3 binding domain comprises a sequence selected from SEQ ID Nos. 248-259, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos. 248-259, or at least about 80% to about 99%. The heavy chain CDR2 (HC CDR2) of the CD3 binding domain comprises a sequence selected from SEQ ID Nos. 260-269, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos. 260-269. The heavy chain CDR3 (HC CDR3) of the CD3 binding domain comprises a sequence selected from SEQ ID Nos. 270-279, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos. 270-279. The light chain CDR1 (LC CDR1) of the CD3 binding domain comprises a sequence selected from SEQ ID Nos. 280-292, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos. 280-292. The light chain CDR2 (LC CDR2) of the CD3 binding domain comprises a sequence selected from SEQ ID Nos. 293-305, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos. 293-305. The light chain CDR3 (LC CDR3) of the CD3 binding domain comprises a sequence selected from SEQ ID Nos. 306-312, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos. 306-312. In one embodiment, the humanized or human CD3 binding domain is a scFv, and a light chain variable region comprising an amino acid sequence described herein, is attached to a heavy chain variable region comprising an amino acid sequence described herein, via a scFv linker. The light chain variable region and heavy chain variable region of a scFv can be in any of the following orientations: light chain variable region-scFv linker-heavy chain variable region or heavy chain variable region-scFv linker-light chain variable region.

In some instances, scFvs which bind to CD3 are produced by linking VH and VL regions together using flexible polypeptide linkers. The scFv molecules comprise a scFv linker (e.g., a Ser-Gly linker) with an optimized length and/or amino acid composition. Accordingly, in some embodiments, the length of the scFv linker is such that the VH or VL domain can associate intermolecularly with the other variable domain to form the CD3 binding site. In certain embodiments, such scFv linkers are “short,” i.e. consist of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acid residues. Thus, in certain instances, the scFv linkers consist of about 12 or less amino acid residues. In the case of 0 amino acid residues, the scFv linker is a peptide bond. In some embodiments, these scFv linkers consist of about 3 to about 15, for example 8, 9 or 10 contiguous amino acid residues. Regarding the amino acid composition of the scFv linkers, peptides are selected that confer flexibility, do not interfere with the variable domains as well as allow inter-chain folding to bring the two variable domains together to form a functional CD3 binding site. For example, scFv linkers comprising glycine and serine residues generally provide protease resistance. In some embodiments, linkers in a scFv comprise glycine and serine residues. The amino acid sequence of the scFv linkers can be optimized, for example, by phage-display methods to improve the CD3 binding and production yield of the scFv. Examples of peptide scFv linkers suitable for linking a variable light domain and a variable heavy domain in a scFv include but are not limited to to (GS)_(n) (SEQ ID No. 197), (GGS)_(n) (SEQ ID No. 198), (GGGS)_(n) (SEQ ID No. 199), (GGSG)_(n) (SEQ ID No. 200), (GGSGG)_(n) (SEQ ID No. 201), (GGGGS)_(n) (SEQ ID No. 202), (GGGGG)_(n) (SEQ ID No. 203), or (GGG)_(n) (SEQ ID No. 204), wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment, the internal linkers L1 and/or L2 independently are (GGGGS)₃ (SEQ ID No. 314), (GGGGS)₄ (SEQ ID No. 315), or (GGGGSGGGS) (SEQ ID No. 246). Variation in the linker length may retain or enhance activity, giving rise to superior efficacy in activity studies.

In some embodiments, CD3 binding domain of EGFR targeting trispecific antigen-binding protein has an affinity to CD3 on CD3 expressing cells with a K_(D) of 1000 nM or less, 500 nM or less, 200 nM or less, 100 nM or less, 80 nM or less, 50 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 1 nM or less, or 0.5 nM or less. In some embodiments, the CD3 binding domain of EGFR targeting trispecific antigen-binding protein has an affinity to CD3ε, γ, or δ with a K_(D) of 1000 nM or less, 500 nM or less, 200 nM or less, 100 nM or less, 80 nM or less, 50 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 1 nM or less, or 0.5 nM or less. In further embodiments, CD3 binding domain of EGFR targeting trispecific antigen-binding protein has low affinity to CD3, i.e., about 100 nM or greater.

The affinity to bind to CD3 can be determined, for example, by the ability of the EGFR targeting trispecific antigen-binding protein itself or its CD3 binding domain to bind to CD3 coated on an assay plate; displayed on a microbial cell surface; in solution; etc. The binding activity of the EGFR targeting trispecific antigen-binding protein itself or its CD3 binding domain of the present disclosure to CD3 can be assayed by immobilizing the ligand (e.g., CD3) or the EGFR targeting trispecific antigen-binding protein itself or its CD3 binding domain, to a bead, substrate, cell, etc. Agents can be added in an appropriate buffer and the binding partners incubated for a period of time at a given temperature. After washes to remove unbound material, the bound protein can be released with, for example, SDS, buffers with a high pH, and the like and analyzed, for example, by Surface Plasmon Resonance (SPR).

In some embodiments, CD3 binding domain of EGFR trispecific antigen-binding protein has an affinity to CD3 on CD3 expressing cells with a K_(D) of 1000 nM or less, 500 nM or less, 200 nM or less, 100 nM or less, 80 nM or less, 50 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 1 nM or less, or 0.5 nM or less. In some embodiments, the CD3 binding domain of EGFR trispecific antigen-binding protein has an affinity to CD3ε, γ, or δ with a K_(D) of 1000 nM or less, 500 nM or less, 200 nM or less, 100 nM or less, 80 nM or less, 50 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 1 nM or less, or 0.5 nM or less. In further embodiments, CD3 binding domain of EGFR trispecific antigen-binding protein has low affinity to CD3, i.e., about 100 nM or greater.

The affinity to bind to CD3 can be determined, for example, by the ability of the EGFR trispecific antigen-binding protein itself or its CD3 binding domain to bind to CD3 coated on an assay plate; displayed on a microbial cell surface; in solution; etc. The binding activity of the EGFR trispecific antigen-binding protein itself or its CD3 binding domain of the present disclosure to CD3 can be assayed by immobilizing the ligand (e.g., CD3) or the EGFR trispecific antigen-binding protein itself or its CD3 binding domain, to a bead, substrate, cell, etc. Agents can be added in an appropriate buffer and the binding partners incubated for a period of time at a given temperature. After washes to remove unbound material, the bound protein can be released with, for example, SDS, buffers with a high pH, and the like and analyzed, for example, by Surface Plasmon Resonance (SPR).

Half-Life Extension Domain

Contemplated herein are domains which extend the half-life of an antigen-binding domain. Such domains are contemplated to include but are not limited to Albumin binding domains, Fc domains, small molecules, and other half-life extension domains known in the art.

Human albumin (ALB) (molecular mass 67 kDa) is the most abundant protein in plasma, present at about 50 mg/ml (600 μM), and has a half-life of around 20 days in humans. ALB serves to maintain plasma pH, contributes to colloidal blood pressure, functions as carrier of many metabolites and fatty acids, and serves as a major drug transport protein in plasma.

Noncovalent association with albumin extends the elimination half-time of short lived proteins. For example, a recombinant fusion of an albumin binding domain to a Fab fragment resulted in an in vivo clearance of 25- and 58-fold and a half-life extension of 26- and 37-fold when administered intravenously to mice and rabbits respectively as compared to the administration of the Fab fragment alone. In another example, when insulin is acylated with fatty acids to promote association with albumin, a protracted effect was observed when injected subcutaneously in rabbits or pigs. Together, these studies demonstrate a linkage between albumin binding and prolonged action.

In one aspect, the EGFR targeting trispecific proteins described herein comprise a half-life extension domain, for example a domain which specifically binds to ALB (also referred to herein as HSA). In some embodiments, the ALB binding domain of the EGFR targeting trispecific antigen-binding protein can be any domain that binds to ALB including but not limited to domains from a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody. In some embodiments, the ALB binding domain is a single chain variable fragments (scFv), single-domain antibody such as a heavy chain variable domain (VH), a light chain variable domain (VL) and a variable domain (VHH) of camelid derived single domain antibody, peptide, ligand or small molecule entity specific for HSA. In certain embodiments, the HSA binding domain is a single-domain antibody. In other embodiments, the HSA binding domain is a peptide. In further embodiments, the HSA binding domain is a small molecule. It is contemplated that in some embodiments the HSA binding domain of EGFR trispecific antigen-binding protein is fairly small and no more than 25 kD, no more than 20 kDa, no more than 15 kDa, or no more than 10 kDa in some embodiments. In certain instances, the ALB binding is 5 kDa or less if it is a peptide or small molecule entity.

The half-life extension domain of EGFR targeting trispecific antigen-binding protein provides for altered pharmacodynamics and pharmacokinetics of the EGFR targeting trispecific antigen-binding protein itself. As above, the half-life extension domain extends the elimination half-time. The half-life extension domain also alters pharmacodynamic properties including alteration of tissue distribution, penetration, and diffusion of the trispecific antigen-binding protein. In some embodiments, the half-life extension domain provides for improved tissue (including tumor) targeting, tissue distribution, tissue penetration, diffusion within the tissue, and enhanced efficacy as compared with a protein without a half-life extension domain. In one embodiment, therapeutic methods effectively and efficiently utilize a reduced amount of the trispecific antigen-binding protein, resulting in reduced side effects, such as reduced non-tumor cell cytotoxicity.

Further, the binding affinity of the half-life extension domain can be selected so as to target a specific elimination half-time in a particular trispecific antigen-binding protein. Thus, in some embodiments, the half-life extension domain has a high binding affinity. In other embodiments, the half-life extension domain has a medium binding affinity. In yet other embodiments, the half-life extension domain has a low or marginal binding affinity. Exemplary binding affinities include KD concentrations at 10 nM or less (high), between 10 nM and 100 nM (medium), and greater than 100 nM (low). As above, binding affinities to ALB are determined by known methods such as Surface Plasmon Resonance (SPR). In some embodiments, ALB binding domains described herein comprise a single domain antibody.

In some embodiments, the half-life extension domain comprises a sequence selected from SEQ ID Nos. 205-214, or a sequence that is at least about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% identical to a sequence selected from SEQ ID Nos. 205-214. In some examples, the half-life extension comprises three heavy chain CDRs (HC CDR1, HC CDR2, and HC CDR3), and three light chain CDRs (LC CDR1, LC CDR2, and LC CDR3). In some examples, the half-life extension comprises three heavy chain CDRs (HC CDR1, HC CDR2, and HC CDR3), or three light chain CDRs. The heavy chain CDR1(HC CDR1) of the half-life extension domain, in some embodiments, comprises a sequence selected from SEQ ID Nos. 215 and 218-220, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos. 215 and 218-220, or at least about 80% to about 99%. The heavy chain CDR2 (HC CDR2) of the half-life extension domain, in some embodiments, comprises a sequence selected from SEQ ID Nos. 216 and 221-226, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos. 216 and 221-226. The heavy chain CDR3 (HC CDR3) of the CD3 binding domain comprises a sequence selected from SEQ ID Nos. 217 and 227-228, or a sequence comprising one or more modifications or substitutions in a sequence selected from SEQ ID Nos. 217 and 227-228.

EGFR Binding Domain

Epidermal growth factor receptor (EGFR, also known as HER1 or ErbB1) is a member of the ErbB/HER family of type 1 receptor tyrosine kinases (RTKs). Other members of this family include ErbB2 (HER2 or Neu), ErbB3 (HER3) and ErbB4 (HER4). Known ligands for EGFR include epidermal growth factor (EGF) and transforming growth factor alpha (TGF-alpha). Ligand binding to EGFR is known to induce tyrosine phosphorylation and receptor dimerization with other ErbB family members.

RTKs such as EGFR function to allow cells to respond to diverse external stimuli. However, aberrant activation and/or overexpression of EGFR is associated with the development and progression of several human cancers. Accordingly, EGFR is a target for anti-cancer therapies. Approved drugs targeting EGFR include small molecule inhibitors such as gefitinib (Iressa®) and erlotinib (Tarceva®), and anti-EGFR antibodies such as cetuximab (Erbitux®) and panitumumab (Vectibix®). Anti-EGFR antibodies are mentioned in, e.g., U.S. Pat. Nos. 4,943,533, 5,844,093, 7,060,808, 7,247,301, 7,595,378, 7,723,484, and 7,939,072. There is still a need for having available further options for the treatment of diseases related to the overexpression of EGFR, including, but not limited to, renal cell carcinoma, pancreatic carcinoma, breast cancer, head and neck cancer, prostate cancer, malignant gliomas, osteosarcoma, colorectal cancer, gastric cancer (e.g., gastric cancer with MET amplification), malignant mesothelioma, multiple myeloma, ovarian cancer, small cell lung cancer, non-small cell lung cancer (e.g., EGFR-dependent non-small cell lung cancer), synovial sarcoma, thyroid cancer, or melanoma. The present disclosure provides, in certain embodiments, EGFR binding proteins, EGFR targeting trispecific proteins containing EGFR binding domains which specifically bind to EGFR on the surface of tumor target cells.

The design of the EGFR targeting trispecific proteins described herein allows the binding domain to EGFR to be flexible in that the binding domain to EGFR can be any type of binding domain, including but not limited to, domains from a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody. In some embodiments, the binding domain to EGFR is a single chain variable fragments (scFv), single-domain antibody such as a heavy chain variable domain (VH), a light chain variable domain (VL) and a variable domain (VHH) of camelid derived single domain antibody. In other embodiments, the binding domain to EGFR is a non-Ig binding domain, i.e., antibody mimetic, such as anticalins, affilins, affibody molecules, affimers, affitins, alphabodies, avimers, DARPins, fynomers, kunitz domain peptides, and monobodies. In further embodiments, the binding domain to EGFR is a ligand or peptide that binds to or associates with EGFR. In yet further embodiments, the binding domain to EGFR is a knottin. In yet further embodiments, the binding domain to EGFR is a small molecular entity.

In some embodiments, the EGFR binding domain is an anti-EGFR antibody or an antibody variant. As used herein, the term “antibody variant” refers to variants and derivatives of an antibody described herein. In certain embodiments, amino acid sequence variants of the anti-EGFR antibodies described herein are contemplated. For example, in certain embodiments amino acid sequence variants of anti-EGFR antibodies described herein are contemplated to improve the binding affinity and/or other biological properties of the antibodies. Exemplary method for preparing amino acid variants include, but are not limited to, introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody.

Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding. In certain embodiments, antibody variants having one or more amino acid substitutions are provided. Sites of interest for substitution mutagenesis include the CDRs and framework regions. Examples of such substitutions are described below. Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, or improved T-cell mediated cytotoxicity (TDCC). Both conservative and non-conservative amino acid substitutions are contemplated for preparing the antibody variants.

In another example of a substitution to create a variant anti-EGFR antibody, one or more hypervariable region residues of a parent antibody are substituted. In general, variants are then selected based on improvements in desired properties compared to a parent antibody, for example, increased affinity, reduced affinity, reduced immunogenicity, increased pH dependence of binding.

In some embodiments, the EGFR binding domain of the EGFR targeting trispecific protein is a single domain antibody such as a heavy chain variable domain (VH), a variable domain (VHH) of a llama derived sdAb, a peptide, a ligand or a small molecule entity specific for EGFR. In some embodiments, the EGFR binding domain of the EGFR targeting trispecific protein described herein is any domain that binds to EGFR including but not limited to domains from a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody. In certain embodiments, the EGFR binding domain is a single-domain antibody. In other embodiments, the EGFR binding domain is a peptide. In further embodiments, the EGFR binding domain is a small molecule.

Generally, it should be noted that the term single domain antibody as used herein in its broadest sense is not limited to a specific biological source or to a specific method of preparation. Single domain antibodies are antibodies whose complementary determining regions are part of a single domain polypeptide. Examples include, but are not limited to, heavy chain antibodies, antibodies naturally devoid of light chains, single domain antibodies derived from conventional 4-chain antibodies, engineered antibodies and single domain scaffolds other than those derived from antibodies. Single domain antibodies may be any of the art, or any future single domain antibodies. Single domain antibodies may be derived from any species including, but not limited to mouse, human, camel, llama, goat, rabbit, bovine. For example, in some embodiments, the single domain antibodies of the disclosure are obtained: (1) by isolating the VHH domain of a naturally occurring heavy chain antibody; (2) by expression of a nucleotide sequence encoding a naturally occurring VHH domain; (3) by “humanization” of a naturally occurring VHH domain or by expression of a nucleic acid encoding a such humanized VHH domain; (4) by “camelization” of a naturally occurring VH domain from any animal species, and in particular from a species of mammal, such as from a human being, or by expression of a nucleic acid encoding such a camelized VH domain; (5) by “camelisation” of a “domain antibody” or “Dab,” or by expression of a nucleic acid encoding such a camelized VH domain; (6) by using synthetic or semi-synthetic techniques for preparing proteins, polypeptides or other amino acid sequences; (7) by preparing a nucleic acid encoding a single domain antibody using techniques for nucleic acid synthesis known in the field, followed by expression of the nucleic acid thus obtained; and/or (8) by any combination of one or more of the foregoing.

In one embodiment, a single domain antibody corresponds to the VHH domains of naturally occurring heavy chain antibodies directed against EGFR. As further described herein, such VHH sequences can generally be generated or obtained by suitably immunizing a species of Llama with EGFR, (i.e., so as to raise an immune response and/or heavy chain antibodies directed against EGFR), by obtaining a suitable biological sample from said Llama (such as a blood sample, serum sample or sample of B-cells), and by generating VHH sequences directed against EGFR, starting from said sample, using any suitable technique known in the field.

In another embodiment, such naturally occurring VHH domains against EGFR, are obtained from naïve libraries of Camelid VHH sequences, for example by screening such a library using EGFR, or at least one part, fragment, antigenic determinant or epitope thereof using one or more screening techniques known in the field. Such libraries and techniques are for example described in WO 99/37681, WO 01/90190, WO 03/025020 and WO 03/035694 Alternatively, improved synthetic or semi-synthetic libraries derived from naïve VHH libraries are used, such as VHH libraries obtained from naïve VHH libraries by techniques such as random mutagenesis and/or CDR shuffling, as for example described in WO 00/43507

In a further embodiment, yet another technique for obtaining VHH sequences directed against EGFR, involves suitably immunizing a transgenic mammal that is capable of expressing heavy chain antibodies (i.e., so as to raise an immune response and/or heavy chain antibodies directed against EGFR), obtaining a suitable biological sample from said transgenic mammal (such as a blood sample, serum sample or sample of B-cells), and then generating VHH sequences directed against EGFR, starting from said sample, using any suitable technique known in the field. For example, for this purpose, the heavy chain antibody-expressing rats or mice and the further methods and techniques described in WO 02/085945 and in WO 04/049794 can be used.

In some embodiments, the EGFR binding domain of this disclosure binds to a protein comprising the sequence of SEQ ID No. 316 (UniProt Accession No. Q504U8). In some embodiments, the EGFR binding domain binds to a protein comprising a truncated sequence compared to SEQ ID No. 316. In some embodiments, the EGFR binding domain binds to a protein comprising the sequence of SEQ ID No. 317 (UniProt Accession No. Q01279). In some embodiments, the EGFR binding domain binds to a protein comprising a truncated sequence compared to SEQ ID No. 317. In some embodiments, the EGFR binding domain binds to a protein comprising the sequence of SEQ ID No. 318 (UniProt Accession No. A0A2K5WK39). In some embodiments, the EGFR binding domain binds to a protein comprising a truncated sequence compared to SEQ ID No. 318.

In some embodiments, the EGFR binding domains disclosed herein recognize full-length EGFR. In certain instances, the EGFR binding domains disclosed herein recognize an epitope within EGFR, such as, in some cases the EGFR targeting trispecific proteins interact with one or more amino acids found within the extracellular domain of human EGFR (e.g., within extracellular domain I, II, III, and/or IV). The epitope to which the antibodies bind may consist of a single contiguous sequence of 3 or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more) amino acids located within the extracellular domain of EGFR. Alternatively, the epitope may consist of a plurality of non-contiguous amino acids (or amino acid sequences) located within the extracellular domain of EGFR.

In some embodiments, the EGFR binding proteins of this disclosure binds to the full length EGFR protein or to a fragment thereof, such as epitope containing fragments within the full length EGFR protein, as described above. In some cases, the epitope containing fragment comprises antigenic or immunogenic fragments and derivatives thereof of the EGFR protein. Epitope containing fragments, including antigenic or immunogenic fragments, are, in some embodiments, 12 amino acids or more, e.g., 20 amino acids or more, 50 or 100 amino acids or more. The EGFR fragments, in some embodiments, comprises 95% or more of the length of the full protein, 90% or more, 75% or 50% or 25% or 10% or more of the length of the full protein. In some embodiments, the epitope-containing fragments of EGFR including antigenic or immunogenic fragments are capable of eliciting a relevant immune response in a patient. Derivatives of EGFR include, in some embodiments, variants on the sequence in which one or more (e.g., 1-20 such as 15 amino acids, or up to 20% such as up to 10% or 5% or 1% by number of amino acids based on the total length of the protein) deletions, insertions or substitutions have been made to the EGFR sequence provided in SEQ ID No. 316, 317, or 318.

In some embodiments, substitutions comprise conservative substitutions. Derivatives and variants of, in some examples, have essentially the same biological function as the protein from which they are derived. For instance, derivatives and variants of EGFR are, in some cases, comparably antigenic or immunogenic to the protein from which they are derived, have either the ligand-binding activity, or the active receptor-complex forming ability, or preferably both, of the protein from which they are derived, and have the same tissue distribution as EGFR.

In some embodiments, the EGFR binding protein specifically binds EGFR with equivalent or better affinity as that of a reference EGFR binding protein, and the EGFR binding protein in such embodiments comprises an affinity matured EGFR binding molecule, and is derived from the EGFR binding parental molecule, comprising one or more amino acid mutations (e.g., a stabilizing mutation, a destabilizing mutation) with respect to the EGFR binding parental molecule. In some embodiments, the affinity matured EGFR binding molecule has superior stability with respect to selected destabilizing agents, as that of a reference EGFR binding parental molecule. In some embodiments, the affinity matured EGFR binding molecule is identified in a process comprising panning of one or more pre-candidate EGFR binding molecules derived from one or more EGFR binding parental molecule, expressed in a phage display library, against a EGFR protein, such as a human EGFR protein. The pre-candidate EGFR binding molecule comprises, in some embodiments, amino acid substitutions in the variable regions, CDRs, or framework residues, relative to a parental molecule.

As used herein, “Phage display” refers to a technique by which variant polypeptides are displayed as fusion proteins to at least a portion of a coat protein on the surface of phage, e.g., filamentous phage, particles. A utility of phage display lies in the fact that large libraries of randomized protein variants can be rapidly and efficiently selected for those sequences that bind to a target molecule with high affinity. Display of peptide and protein libraries on phage has been used for screening millions of polypeptides for ones with specific binding properties. Polyvalent phage display methods have been used for displaying small random peptides and small proteins through fusions to either gene III or gene VIII of filamentous phage. Wells and Lowman, Curr. Opin. Struct. Biol, 3:355-362 (1992), and references cited therein. In monovalent phage display, a protein or peptide library is fused to a gene III or a portion thereof, and expressed at low levels in the presence of wild type gene III protein so that phage particles display one copy or none of the fusion proteins. Avidity effects are reduced relative to polyvalent phage so that selection is on the basis of intrinsic ligand affinity, and phagemid vectors are used, which simplify DNA manipulations. Lowman and Wells, Methods: A companion to Methods in Enzymology, 3:205-0216 (1991).

In some embodiments, the panning comprises using varying binding times and concentrations to identify EGFR binding molecules with increased or decreased on-rates, from pre-candidate EGFR binding molecules. In some embodiments, the panning comprises using varying wash times to identify EGFR binding molecules with increased or decreased off-rates, from pre-candidate EGFR molecules. In some embodiments, the panning comprises using both varying binding times and varying wash times. In some embodiments, one or more stabilizing mutations are combined to increase the stability of the affinity matured EGFR binding molecule, for example, by shuffling to create a second-stage combinatorial library from such mutants and conducting a second round of panning followed by a binding selection.

In some embodiments, the affinity matured EGFR binding molecule comprises an equivalent or better affinity to a EGFR protein (such as human EGFR protein) as that of a EGFR binding parental molecule, but that has reduced cross reactivity, or in some embodiments, increased cross reactivity, with selected substances, such as ligands, proteins, antigens, or the like, other than the EGFR epitope for which the EGFR binding parental molecule is specific, or is designed to be specific for. In regard to the latter, an affinity matured EGFR binding molecule, in some embodiments, is more successfully tested in animal models if the affinity matured EGFR binding molecule is reacted with both human EGFR and the corresponding target of the animal model, e.g. mouse EGFR or cynomolgus EGFR. In some embodiments, the parental EGFR binding molecule binds to human EGFR with an affinity of about 10 nM or less, and to cynomolgus EGFR with an affinity of about 15 nM or less. In some embodiments, the affinity matured EGFR binding molecule, identified after one round of panning, binds to human EGFR with an affinity of about 5 nM or less, and to cynomolgus EGFR with an affinity of about 7.5 nM or less. In some embodiments, the affinity matured EGFR binding molecule, identified after two rounds of panning, binds to human EGFR with an affinity of about 2.5 nM or less, and to cynomolgus EGFR with an affinity of about 3.5 nM or less.

In some embodiments, the EGFR binding protein comprises an antigen-specific binding domain polypeptide that specifically bind to targets, such as targets on diseased cells, or targets on other cells that support the diseased state, such as targets on stromal cells that support tumor growth or targets on immune cells that support disease-mediated immunosuppression. In some examples, the antigen-specific binding domain includes antibodies, single chain antibodies, Fabs, Fv, T-cell receptor binding domains, ligand binding domains, receptor binding domains, domain antibodies, single domain antibodies, minibodies, nanobodies, peptibodies, or various other antibody mimics (such as affimers, affitins, alphabodies, atrimers, CTLA4-based molecules, adnectins, anticalins, Kunitz domain-based proteins, avimers, knottins, fynomers, darpins, affibodies, affilins, monobodies and armadillo repeat protein-based proteins).

In some embodiments, an anti-EGFR single domain antibody of the EGFR targeting trispecific protein comprises a single domain antibody with an amino acid sequence that corresponds to the amino acid sequence of a naturally occurring VHH domain, but that has been “humanized,” i.e., by replacing one or more amino acid residues in the amino acid sequence of said naturally occurring VHH sequence (and in particular in the framework sequences) by one or more of the amino acid residues that occur at the corresponding position(s) in a VH domain from a conventional 4-chain antibody from a human being (e.g., as indicated above). This can be performed in a manner known in the field, which will be clear to the skilled person, for example on the basis of the further description herein. Again, it should be noted that such humanized anti-EGFR single domain antibodies of the disclosure are obtained in any suitable manner known per se (i.e., as indicated under points (1)-(8) above) and thus are not strictly limited to polypeptides that have been obtained using a polypeptide that comprises a naturally occurring VHH domain as a starting material. In some additional embodiments, a single domain anti-EGFR antibody, as described herein, comprises a single domain antibody with an amino acid sequence that corresponds to the amino acid sequence of a naturally occurring VH domain, but that has been “camelized” i.e., by replacing one or more amino acid residues in the amino acid sequence of a naturally occurring VH domain from a conventional 4-chain antibody by one or more of the amino acid residues that occur at the corresponding position(s) in a VHH domain of a heavy chain antibody. Such “camelizing” substitutions are preferably inserted at amino acid positions that form and/or are present at the VH-VL interface, and/or at the so-called Camelidae hallmark residues (see for example WO 94/04678 and Davies and Riechmann (1994 and 1996)). Preferably, the VH sequence that is used as a starting material or starting point for generating or designing the camelized single domain is preferably a VH sequence from a mammal, more preferably the VH sequence of a human being, such as a VH3 sequence. However, it should be noted that such camelized anti-EGFR single domain antibodies of the disclosure, in certain embodiments, are obtained in any suitable manner known in the field (i.e., as indicated under points (1)-(8) above) and thus are not strictly limited to polypeptides that have been obtained using a polypeptide that comprises a naturally occurring VH domain as a starting material. For example, as further described herein, both “humanization” and “camelization” is performed by providing a nucleotide sequence that encodes a naturally occurring VHH domain or VH domain, respectively, and then changing, one or more codons in said nucleotide sequence in such a way that the new nucleotide sequence encodes a “humanized” or “camelized” single domain antibody, respectively. This nucleic acid can then be expressed, so as to provide a desired anti-EGFR single domain antibody of the disclosure. Alternatively, in other embodiments, based on the amino acid sequence of a naturally occurring VHH domain or VH domain, respectively, the amino acid sequence of the desired humanized or camelized anti-EGFR single domain antibody of the disclosure, respectively, are designed and then synthesized de novo using known techniques for peptide synthesis. In some embodiments, based on the amino acid sequence or nucleotide sequence of a naturally occurring VHH domain or VH domain, respectively, a nucleotide sequence encoding the desired humanized or camelized anti-EGFR single domain antibody of the disclosure, respectively, is designed and then synthesized de novo using known techniques for nucleic acid synthesis, after which the nucleic acid thus obtained is expressed in using known expression techniques, so as to provide the desired anti-EGFR single domain antibody of the disclosure.

Other suitable methods and techniques for obtaining the anti-EGFR single domain antibody of the disclosure and/or nucleic acids encoding the same, starting from naturally occurring VH sequences or VHH sequences for example comprises combining one or more parts of one or more naturally occurring VH sequences (such as one or more framework (FR) sequences and/or complementarity determining region (CDR) sequences), one or more parts of one or more naturally occurring VHH sequences (such as one or more FR sequences or CDR sequences), and/or one or more synthetic or semi-synthetic sequences, in a suitable manner, so as to provide an anti-EGFR single domain antibody of the disclosure or a nucleotide sequence or nucleic acid encoding the same.

In some embodiments, the EGFR binding domain is an anti-EGFR specific antibody comprising a heavy chain variable complementarity determining region CDR1, a heavy chain variable CDR2, a heavy chain variable CDR3, a light chain variable CDR1, a light chain variable CDR2, and a light chain variable CDR3. In some embodiments, the EGFR binding domain comprises any domain that binds to EGFR including but not limited to domains from a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, or antigen binding fragments such as single domain antibodies (sdAb), Fab, Fab′, F(ab)2, and Fv fragments, fragments comprised of one or more CDRs, single-chain antibodies (e.g., single chain Fv fragments (scFv)), disulfide stabilized (dsFv) Fv fragments, heteroconjugate antibodies (e.g., bispecific antibodies), pFv fragments, heavy chain monomers or dimers, light chain monomers or dimers, and dimers consisting of one heavy chain and one light chain. In some embodiments, the EGFR binding domain is a single domain antibody. In some embodiments, the anti-EGFR single domain antibody comprises heavy chain variable complementarity determining regions (CDR), CDR1, CDR2, and CDR3.

In some embodiments, the EGFR binding domain is a polypeptide comprising an amino acid sequence that is comprised of four framework regions/sequences (f1-f4) interrupted by three complementarity determining regions/sequences, as represented by the formula: f1-r1-f2-r2-f3-r3-f4, wherein r1, r2, and r3 are complementarity determining regions CDR1, CDR2, and CDR3, respectively, and f1, f2, f3, and f4 are framework residues. The framework residues of the EGFR binding protein of the present disclosure comprise, for example, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, or 94 amino acid residues, and the complementarity determining regions comprise, for example, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 amino acid residues. In some embodiments, the EGFR binding domain comprises an amino acid sequence selected from SEQ ID Nos. 1-49.

In some embodiments, the EGFR binding domains described herein comprise a polypeptide having a sequence selected from SEQ ID Nos. 1-49, subsequences thereof, and variants thereof. In some embodiments, the EGFR binding protein comprises at least 70%-95% or more homology to a sequence selected from SEQ ID Nos. 1-49, subsequences thereof, and variants thereof. In some embodiments, the EGFR binding protein comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more homology to a sequence selected from SEQ ID Nos. 1-49, subsequences thereof, and variants thereof. In some embodiments, the EGFR binding protein comprises at least 70%-95% or more identity to a sequence selected from SEQ ID Nos. 1-49, subsequences thereof, and variants thereof. In some embodiments, the EGFR binding protein comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity to a sequence selected from SEQ ID Nos. 1-49, subsequences thereof, and variants thereof.

In some embodiments, the CDR1 comprises the amino acid sequence as set forth in any one of SEQ ID Nos. 50-98 or a variant having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in any one of SEQ ID Nos. 50-98. In some embodiments, the CDR2 comprises a sequence as set forth in any one of SEQ ID Nos. 99-147 or a variant having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in any one of SEQ ID Nos. 99-147. In some embodiments, the CDR3 comprises a sequence as set forth in any one of SEQ ID Nos. 148-196 or a variant having one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions in any one of SEQ ID Nos. 148-196.

In various embodiments, the EGFR binding domain of the present disclosure is at least about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to an amino acid sequence selected from SEQ ID Nos. 1-49.

In various embodiments, a complementarity determining region of the EGFR binding domain of the present disclosure is at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to an amino acid sequence set forth in any one of SEQ ID Nos. 50-98.

In various embodiments, a complementarity determining region of the EGFR binding domain of the present disclosure is at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to an amino acid sequence set forth in any one of SEQ ID Nos. 99-147.

In various embodiments, a complementarity determining region of the EGFR binding domain of the present disclosure is at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to an amino acid sequence set forth in any one of SEQ ID Nos. 148-196.

In various embodiments, an EGFR targeting trispecific protein of the present disclosure is at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to an amino acid sequence set forth in any one of SEQ ID Nos. 319-367. In various embodiments, an EGFR targeting trispecific protein of the present disclosure is at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to an amino acid sequence set forth in any one of SEQ ID Nos. 358 and SEQ ID No. 363.

In some embodiments, the EGFR binding domain is cross-reactive with human cynomolgus and mouse EGFR. In some embodiments, the EGFR binding domain is specific for human EGFR. In certain embodiments, the EGFR binding domains disclosed herein bind to human EGFR with a human Kd (hKd). In certain embodiments, the EGFR binding domains disclosed herein bind to cynomolgus EGFR with a cyno Kd (cKd). In certain embodiments, the EGFR binding domains disclosed herein bind to cynomolgus EGFR with a mouse Kd (mKd). In certain embodiments, the EGFR binding domains disclosed herein bind to both cynomolgus EGFR and a human EGFR, with a cyno Kd (cKd) and a human Kd (hKd), respectively. In certain embodiments, the EGFR binding domains disclosed herein bind to cynomolgus EGFR, mouse EGFR, and a human EGFR, with a cyno Kd (cKd), mouse Kd (mKd), and a human Kd (hKd), respectively. In some embodiments, the EGFR binding protein binds to human, mouse and cynomolgus EGFR with comparable binding affinities (i.e., hKd, mKd and cKd values do not differ by more than ±10%). In some embodiments, the hKd, mKd and the cKd range from about 0.1 nM to about 500 nM. In some embodiments, the hKd, mKd and the cKd range from about 0.1 nM to about 450 nM. In some embodiments, the hKd, mKd and the cKd range from about 0.1 nM to about 400 nM. In some embodiments, the hKd, mKd and the cKd range from about 0.1 nM to about 350 nM. In some embodiments, the hKd, mKd and the cKd range from about 0.1 nM to about 300 nM. In some embodiments, the hKd, mKd and the cKd range from about 0.1 nM to about 250 nM. In some embodiments, the hKd, mKd and the cKd range from about 0.1 nM to about 200 nM. In some embodiments, the hKd, mKd and the cKd range from about 0.1 nM to about 150 nM. In some embodiments, the hKd, mKd and the cKd range from about 0.1 nM to about 100 nM. In some embodiments, the hKd, mKd and the cKd range from about 0.1 nM to about 90 nM. In some embodiments, the hKd, mKd and the cKd range from about 0.2 nM to about 80 nM. In some embodiments, the hKd, mKd and the cKd range from about 0.3 nM to about 70 nM. In some embodiments, the hKd, mKd and the cKd range from about 0.4 nM to about 50 nM. In some embodiments, the hKd, mKd and the cKd range from about 0.5 nM to about 30 nM. In some embodiments, the hKd, mKd and the cKd range from about 0.6 nM to about 10 nM. In some embodiments, the hKd, mKd and the cKd range from about 0.7 nM to about 8 nM. In some embodiments, the hKd, mKd and the cKd range from about 0.8 nM to about 6 nM. In some embodiments, the hKd, mKd and the cKd range from about 0.9 nM to about 4 nM. In some embodiments, the hKd, mKd and the cKd range from about 1 nM to about 2 nM.

In some embodiments, any of the foregoing EGFR binding domains (e.g., anti-EGFR single domain antibodies of SEQ ID Nos. 1-49) are affinity peptide tagged for ease of purification. In some embodiments, the affinity peptide tag is six consecutive histidine residues, also referred to as 6×-his (SEQ ID No. 247).

In certain embodiments, the EGFR binding domains of the present disclosure preferentially bind membrane bound EGFR over soluble EGFR Membrane bound EGFR refers to the presence of EGFR in or on the cell membrane surface of a cell that expresses EGFR. Soluble EGFR refers to EGFR that is no longer on in or on the cell membrane surface of a cell that expresses or expressed EGFR. In certain instances, the soluble EGFR is present in the blood and/or lymphatic circulation in a subject. In one embodiment, the EGFR binding domains bind membrane-bound EGFR at least 5 fold, 10 fold, 15 fold, 20 fold, 25 fold, 30 fold, 40 fold, 50 fold, 100 fold, 500 fold, or 1000 fold greater than soluble EGFR. In one embodiment, the EGFR targeting trispecific antigen binding proteins of the present disclosure preferentially bind membrane-bound EGFR 30 fold greater than soluble EGFR. Determining the preferential binding of an antigen binding protein to membrane bound EGFR over soluble EGFR can be readily determined using binding assays. It is contemplated that in some embodiments the EGFR binding protein is fairly small and no more than 25 kDa, no more than 20 kDa, no more than 15 kDa, or no more than 10 kDa in some embodiments. In certain instances, the EGFR binding protein is 5 kDa or less if it is a peptide or small molecule entity.

In other embodiments, the EGFR binding proteins described herein comprise small molecule entity (SME) binders for EGFR. SME binders are small molecules averaging about 500 to 2000 Da in size and are attached to the EGFR binding proteins by known methods, such as sortase ligation or conjugation. In these instances, the EGFR binding protein comprises a domain comprising a sortase recognition sequence, e.g., LPETG (SEQ ID No. 208). To attach a SME binder to EGFR binding protein comprising a sortase recognition sequence, the protein is incubated with a sortase and a SME binder whereby the sortase attaches the SME binder to the recognition sequence. In yet other embodiments, the EGFR binding proteins described herein comprise a knottin peptide for binding EGFR. Knottins are disufide-stabilized peptides with a cysteine knot scaffold and have average sizes about 3.5 kDa. Knottins have been contemplated for binding to certain tumor molecules such as EGFR. In further embodiments, the EGFR binding proteins described herein comprise a natural EGFR ligand.

In some embodiments, the EGFR binding protein comprises more than one domain and are of a single-polypeptide design with flexible linkage of the domains. This allows for facile production and manufacturing of the EGFR binding proteins as they can be encoded by single cDNA molecule to be easily incorporated into a vector. Further, in some embodiments where the EGFR binding proteins described herein are a monomeric single polypeptide chain, there are no chain pairing issues or a requirement for dimerization. It is contemplated that, in such embodiments, the EGFR binding proteins described herein have a reduced tendency to aggregate.

In the EGFR binding proteins comprising more than one domain, the domains are linked by one or more internal linker. In certain embodiments, the internal linkers are “short,” i.e., consist of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acid residues. Thus, in certain instances, the internal linkers consist of about 12 or less amino acid residues. In the case of 0 amino acid residues, the internal linker is a peptide bond. In certain embodiments, the internal linkers are “long,” i.e., consist of 15, 20 or 25 amino acid residues. In some embodiments, the internal linkers consist of about 3 to about 15, for example 8, 9 or 10 contiguous amino acid residues. Regarding the amino acid composition of the internal linkers, peptides are selected with properties that confer flexibility to the EGFR binding proteins, do not interfere with the binding domains as well as resist cleavage from proteases. For example, glycine and senile residues generally provide protease resistance. Examples of internal linkers suitable for linking the domains in the EGFR binding proteins include but are not limited to (GS)_(n) (SEQ ID No. 197), (GGS)_(n) (SEQ ID No. 198), (GGGS)_(n) (SEQ ID No. 199), (GGSG)_(n) (SEQ ID No. 200), (GGSGG)_(n) (SEQ ID No. 201), (GGGGS)_(n) (SEQ ID No. 202), (GGGGG)_(n) (SEQ ID No. 203), or (GGG)_(n) (SEQ ID No. 204), wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment, the linker is (GGGGSGGGGSGGGGSGGGGS)(SEQ ID No. 315), (GGGGSGGGGSGGGGS) (SEQ ID No. 314), or (GGGGSGGGS) (SEQ ID No. 246).

In some cases, where the EGFR binding protein comprises more than one domain, the domains within the EGFR binding proteins are conjugated using an enzymatic site-specific conjugation method which involves the use of a mammalian or bacterial transglutaminase enzyme. Microbial transglutaminases (mTGs) are versatile tools in modern research and biotechnology. The availability of large quantities of relatively pure enzymes, ease of use, and lack of regulation by calcium and guanosine-5′-triphosphate (GTP) has propelled mTG to be the main cross-linking enzyme used in both the food industry and biotechnology. Currently, mTGs are used in many applications to attach proteins and peptides to small molecules, polymers, surfaces, DNA, as well as to other proteins. See, e.g., Pavel Strp, Veracity of microbial transglutaminase, Bioconjugate Chem. 25, 5, 855-862).

In some examples are provided EGFR binding proteins comprising more than one domain, wherein one of the domains comprises an acceptor glutamine in a constant region, which can then be conjugated to another domain via a lysine-based linker (e.g., any primary amine chain which is a substrate for TGase, e.g. comprising an alkylamine, oxoamine) wherein the conjugation occurs exclusively on one or more acceptor glutamine residues present in the targeting moiety outside of the antigen combining site (e.g., outside a variable region, in a constant region). Conjugation thus does not occur on a glutamine, e.g. an at least partly surface exposed glutamine, within the variable region. The EGFR binding protein, in some examples, is formed by reacting one of the domains with a lysine-based linker in the presence of a TGase.

In some embodiments, where one or more domains within the EGFR binding proteins are directly joined, a hybrid vector is made where the DNA encoding the directly joined domains are themselves directly ligated to each other. In some embodiments, where linkers are used, a hybrid vector is made where the DNA encoding one domain is ligated to the DNA encoding one end of a linker moiety and the DNA encoding another domain is ligated to the other end of the linker moiety.

In some embodiments, the EGFR binding protein is a single chain variable fragments (scFv), single-domain antibody such as a heavy chain variable domain (VH), a light chain variable domain (VL) and a variable domain (VHH) of camelid derived single domain antibody. In other embodiments, the EGFR binding protein is a non-Ig binding domain, i.e., an antibody mimetic, such as anticalins, affilins, affibody molecules, affimers, affitins, alphabodies, avimers, DARPins, fynomers, kunitz domain peptides, and monobodies. In further embodiments, the EGFR binding protein is a ligand or peptide that binds to or associates with EGFR. In yet further embodiments, the EGFR binding protein is a knottin. In yet further embodiments, the binding domain to EGFR is a small molecular entity.

In some embodiments, the EGFR binding proteins as set forth above are fused to an Fc region from any species, including but not limited to, human immunoglobulin, such as human IgG1, a human IgG2, a human IgG3, human IgG4, to generate Fc-fusion proteins. In some embodiments, the Fc-fusion proteins of this disclosure have extended half-life compared to an otherwise identical EGFR binding protein. In some embodiments, the Fc-fusion EGFR binding proteins of this disclosure contain inter alia one or more additional amino acid residue substitutions, mutations and/or modifications, e.g., in the Fc region, which result in a binding protein with preferred characteristics including, but not limited to: altered pharmacokinetics, extended serum half-life.

In some embodiments, such Fc-fused EGFR binding proteins provide extended half-lives in a mammal, such as in a human, of greater than 5 days, greater than 10 days, greater than 15 days, greater than 20 days, greater than 25 days, greater than 30 days, greater than 35 days, greater than 40 days, greater than 45 days, greater than 2 months, greater than 3 months, greater than 4 months, or greater than 5 months. The increased half-life, in some cases, results in a higher serum titer which thus reduces the frequency of the administration of the EGFR binding proteins and/or reduces the concentration of the antibodies to be administered. Binding to human FcRn in vivo and serum half-life of human FcRn high affinity binding polypeptides is assayed, in some examples, in transgenic mice or transfected human cell lines expressing human FcRn, or in primates to which the polypeptides with a variant Fc region are administered.

The EGFR binding proteins, in some cases, are differentially modified during or after production, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications are carried out by techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH4, acetylation, formylation, oxidation, reduction, metabolic synthesis in the presence of tunicamycin, etc.

Various post-translational modifications of the EGFR binding proteins also encompassed by the disclosure include, for example, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends, attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of prokaryotic host cell expression. Moreover, the EGFR binding proteins are, in some cases, modified with a detectable label, such as an enzymatic, fluorescent, radioisotopic or affinity label to allow for detection and isolation of the modulator.

In some embodiments, the EGFR binding proteins of the disclosure are monovalent or multivalent bivalent, trivalent, etc.). As used herein, the term “valency” refers to the number of potential target binding sites associated with an antibody. Each target binding site specifically binds one target molecule or specific position or locus on a target molecule. When an antibody is monovalent, each binding site of the molecule will specifically bind to a single antigen position or epitope. When an antibody comprises more than one target binding site (multivalent), each target binding site may specifically bind the same or different molecules (e.g., may bind to different ligands or different antigens, or different epitopes or positions on the same antigen).

Integration into Chimeric Antigen Receptors (CAR)

The EGFR targeting trispecific antigen binding proteins of the present disclosure can, in certain examples, be incorporated into a chimeric antigen receptor (CAR). An engineered immune effector cell, e.g., a T cell or NK cell, can be used to express a CAR that includes an anti-EGFR targeting trispecific protein containing an anti-EGFR single domain antibody as described herein. In one embodiment, the CAR including an anti-EGFR targeting trispecific protein as described herein is connected to a transmembrane domain via a hinge region, and further a costimulatory domain, e.g., a functional signaling domain obtained from OX40, CD27, CD28, CD5, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), or 4-1BB. In some embodiments, the CAR further comprises a sequence encoding an intracellular signaling domain, such as 4-1BB and/or CD3 zeta.

Tumor Growth Reduction Properties

In certain embodiments, the EGFR targeting trispecific proteins of the disclosure reduce the growth of tumor cells in vivo when administered to a subject who has tumor cells that express EGFR. Measurement of the reduction of the growth of tumor cells can be determined by multiple different methodologies, such as tumor volume measured by microCT, PET, caliper etc. Non-limiting examples include direct measurement of tumor dimension, measurement of excised tumor mass and comparison to control subjects, measurement via imaging techniques (e.g., CT or MRI) that may or may not use isotopes or luminescent molecules (e.g., luciferase) for enhanced analysis, and the like. In specific embodiments, administration of the trispecific proteins of the disclosure results in a reduction of in vivo growth of tumor cells as compared to a control antigen binding agent by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%, with an about 100% reduction in tumor growth indicating a complete response and disappearance of the tumor. In further embodiments, administration of the trispecific proteins of the disclosure results in a reduction of in vivo growth of tumor cells as compared to a control antigen binding agent by about 50-100%, about 75-100% or about 90-100%. In further embodiments, administration of the trispecific proteins of the disclosure results in a reduction of in vivo growth of tumor cells as compared to a control antigen binding agent by about 50-60%, about 60-70%, about 70-80%, about 80-90%, or about 90-100%.

EGFR Trispecific Protein Modifications

The EGFR targeting trispecific proteins described herein encompass derivatives or analogs in which (i) an amino acid is substituted with an amino acid residue that is not one encoded by the genetic code, (ii) the mature polypeptide is fused with another compound such as polyethylene glycol, or (iii) additional amino acids are fused to the protein, such as a leader or secretory sequence or a sequence for purification of the protein.

Typical modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Modifications are made anywhere in EGFR targeting trispecific proteins described herein, including the peptide backbone, the amino acid side-chains, and the amino or carboxyl termini. Certain common peptide modifications that are useful for modification of EGFR targeting trispecific proteins include glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation, blockage of the amino or carboxyl group in a polypeptide, or both, by a covalent modification, and ADP-ribosylation. In some embodiments, derivatives of the EGFR targeting trispecific proteins as described herein comprise immunoreactive modulator derivatives and antigen binding molecules comprising one or more modifications.

Polynucleotides Encoding EGFR Targeting Trispecific Proteins

Also provided, in some embodiments, are polynucleotide molecules encoding an anti-EGFR trispecific binding protein described herein. In some embodiments, the polynucleotide molecules are provided as a DNA construct. In other embodiments, the polynucleotide molecules are provided as a messenger RNA transcript.

The polynucleotide molecules are constructed by known methods such as by combining the genes encoding the three binding domains either separated by peptide linkers or, in other embodiments, directly linked by a peptide bond, into a single genetic construct operably linked to a suitable promoter, and optionally a suitable transcription terminator, and expressing it in bacteria or other appropriate expression system such as, for example CHO cells. In the embodiments where the EGFR binding domain is a small molecule, the polynucleotides contain genes encoding the CD3 binding domain and the half-life extension domain. In the embodiments where the half-life extension domain is a small molecule, the polynucleotides contain genes encoding the domains that bind to CD3 and EGFR. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. The promoter is selected such that it drives the expression of the polynucleotide in the respective host cell.

In some embodiments, the polynucleotide is inserted into a vector, preferably an expression vector, which represents a further embodiment. This recombinant vector can be constructed according to known methods. Vectors of particular interest include plasmids, phagemids, phage derivatives, virii (e.g., retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, lentiviruses, and the like), and cosmids.

A variety of expression vector/host systems may be utilized to contain and express the polynucleotide encoding the polypeptide of the described trispecific antigen-binding protein. Examples of expression vectors for expression in E. coli are pSKK (Le Gall et al., J Immunol Methods. (2004) 285(1):111-27) or pcDNA5 (Invitrogen) for expression in mammalian cells.

Thus, the EGFR targeting trispecific proteins as described herein, in some embodiments, are produced by introducing a vector encoding the protein as described above into a host cell and culturing said host cell under conditions whereby the protein domains are expressed, may be isolated and, optionally, further purified.

Pharmaceutical Compositions

Also provided, in some embodiments, are pharmaceutical compositions comprising an EGFR binding protein or an anti-EGFR trispecific binding protein described herein, a vector comprising the polynucleotide encoding the polypeptide of the EGFR binding protein, or the EGFR targeting trispecific proteins or a host cell transformed by such a vector and at least one pharmaceutically acceptable carrier. The term “pharmaceutically acceptable carrier” includes, but is not limited to, any carrier that does not interfere with the effectiveness of the biological activity of the ingredients and that is not toxic to the patient to whom it is administered. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Such carriers can be formulated by conventional methods and can be administered to the subject at a suitable dose. Preferably, the compositions are sterile. These compositions may also contain adjuvants such as preservative, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents. A further embodiment provides one or more of the above described EGFR binding proteins or the EGFR targeting trispecific proteins packaged in lyophilized form, or packaged in an aqueous medium.

In some embodiments of the pharmaceutical compositions, the EGFR binding proteins or the EGFR targeting trispecific proteins described herein are encapsulated in nanoparticles. In some embodiments, the nanoparticles are fullerenes, liquid crystals, liposome, quantum dots, superparamagnetic nanoparticles, dendrimers, or nanorods. In other embodiments of the pharmaceutical compositions, the EGFR binding protein or the EGFR trispecific antigen-binding protein is attached to liposomes. In some instances, EGFR binding protein or the EGFR trispecific antigen-binding protein are conjugated to the surface of liposomes. In some instances, the EGFR binding protein or the EGFR trispecific antigen-binding protein are encapsulated within the shell of a liposome. In some instances, the liposome is a cationic liposome.

The EGFR binding protein or the EGFR targeting trispecific proteins described herein are contemplated for use as a medicament. Administration is effected by different ways, e.g., by intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration. In some embodiments, the route of administration depends on the kind of therapy and the kind of compound contained in the pharmaceutical composition. The dosage regimen will be determined by the attending physician and other clinical factors. Dosages for any one patient depends on many factors, including the patient's size, body surface area, age, sex, the particular compound to be administered, time and route of administration, the kind of therapy, general health and other drugs being administered concurrently. An “effective dose” refers to amounts of the active ingredient that are sufficient to affect the course and the severity of the disease, leading to the reduction or remission of such pathology and may be determined using known methods.

In some embodiments, the EGFR binding proteins or the EGFR targeting trispecific proteins of this disclosure are administered at a dosage of up to 10 mg/kg at a frequency of once a week. In some cases, the dosage ranges from about 1 ng/kg to about 10 mg/kg. In some embodiments, the dose is from about 1 ng/kg to about 10 ng/kg, about 5 ng/kg to about 15 ng/kg, about 12 ng/kg to about 20 ng/kg, about 18 ng/kg to about 30 ng/kg, about 25 ng/kg to about 50 ng/kg, about 35 ng/kg to about 60 ng/kg, about 45 ng/kg to about 70 ng/kg, about 65 ng/kg to about 85 ng/kg, about 80 ng/kg to about 1 μg/kg, about 0.5 μg/kg to about 5 μg/kg, about 2 μg/kg to about 10 μg/kg, about 7 μg/kg to about 15 μg/kg, about 12 μg/kg to about 25 μg/kg, about 20 μg/kg to about 50 μg/kg, about 35 μg/kg to about 70 μg/kg, about 45 μg/kg to about 80 μg/kg, about 65 μg/kg to about 90 μg/kg, about 85 μg/kg to about 0.1 mg/kg, about 0.095 mg/kg to about 10 mg/kg. In some cases, the dosage is about 0.1 mg/kg to about 0.2 mg/kg; about 0.25 mg/kg to about 0.5 mg/kg, about 0.45 mg/kg to about 1 mg/kg, about 0.75 mg/kg to about 3 mg/kg, about 2.5 mg/kg to about 4 mg/kg, about 3.5 mg/kg to about 5 mg/kg, about 4.5 mg/kg to about 6 mg/kg, about 5.5 mg/kg to about 7 mg/kg, about 6.5 mg/kg to about 8 mg/kg, about 7.5 mg/kg to about 9 mg/kg, or about 8.5 mg/kg to about 10 mg/kg. The frequency of administration, in some embodiments, is about less than daily, every other day, less than once a day, twice a week, weekly, once in 7 days, once in two weeks, once in two weeks, once in three weeks, once in four weeks, or once a month. In some cases, the frequency of administration is weekly. In some cases, the frequency of administration is weekly and the dosage is up to 10 mg/kg. In some cases, duration of administration is from about 1 day to about 4 weeks or longer.

Methods of Treatment

Also provided herein, in some embodiments, are methods and uses for stimulating the immune system of an individual in need thereof comprising administration of an anti-EGFR binding protein or an anti-EGFR targeting trispecific protein as described herein. In some instances, the administration of an anti-EGFR binding protein or an anti-EGFR targeting trispecific protein described herein induces and/or sustains cytotoxicity towards a cell expressing a target antigen. In some instances, the cell expressing a target antigen is a cancer or tumor cell, a virally infected cell, a bacterially infected cell, an autoreactive T or B cell, damaged red blood cells, arterial plaques, or fibrotic tissue.

Also provided herein are methods and uses for a treatment of a disease, disorder or condition associated with a target antigen comprising administering to an individual in need thereof an anti-EGFR binding protein or an anti-EGFR targeting trispecific protein described herein. Diseases, disorders or conditions associated with a target antigen include, but are not limited to, viral infection, bacterial infection, auto-immune disease, transplant rejection, atherosclerosis, or fibrosis. In other embodiments, the disease, disorder or condition associated with a target antigen is a proliferative disease, a tumorous disease, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, a viral disease, an allergic reaction, a parasitic reaction, a graft-versus-host disease or a host-versus-graft disease. In one embodiment, the disease, disorder or condition associated with a target antigen is cancer. Cancers that can be treated, prevented, or managed by the EGFR binding proteins or EGFR targeting trispecific proteins of the present disclosure, and methods of using them, include but are not limited to cancers of an epithelial cell origin. Examples of such cancers include the following: leukemias, such as but not limited to, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemias, such as, myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia leukemias and myelodysplastic syndrome; chronic leukemias, such as but not limited to, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, hairy cell leukemia; polycythemia vera; lymphomas such as but not limited to Hodgkin's disease, non-Hodgkin's disease; multiple myelomas such as but not limited to smoldering multiple myeloma, nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma and extramedullary plasmacytoma; Waldenstrom's macroglobulinemia; monoclonal gammopathy of undetermined significance; benign monoclonal gammopathy; heavy chain disease; bone and connective tissue sarcomas such as but not limited to bone sarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft-tissue sarcomas, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, neurilemmoma, rhabdomyosarcoma, synovial sarcoma; brain tumors such as but not limited to, glioma, astrocytoma, brain stem glioma, ependymoma, oligodendroglioma, nonglial tumor, acoustic neurinoma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, primary brain lymphoma; breast cancer including but not limited to ductal carcinoma, adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mucinous breast cancer, tubular breast cancer, papillary breast cancer, Paget's disease, and inflammatory breast cancer; adrenal cancer such as but not limited to pheochromocytom and adrenocortical carcinoma; thyroid cancer such as but not limited to papillary or follicular thyroid cancer, medullary thyroid cancer and anaplastic thyroid cancer; pancreatic cancer such as but not limited to, insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor; pituitary cancers such as but limited to Cushing's disease, prolactin-secreting tumor, acromegaly, and diabetes insipius; eye cancers such as but not limited to ocular melanoma such as iris melanoma, choroidal melanoma, and cilliary body melanoma, and retinoblastoma; vaginal cancers such as squamous cell carcinoma, adenocarcinoma, and melanoma; vulvar cancer such as squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; cervical cancers such as but not limited to, squamous cell carcinoma, and adenocarcinoma; uterine cancers such as but not limited to endometrial carcinoma and uterine sarcoma; ovarian cancers such as but not limited to, ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; esophageal cancers such as but not limited to, squamous cancer, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; stomach cancers such as but not limited to, adenocarcinoma, fungating (polypoid), ulcerating, superficial spreading, diffusely spreading, malignant lymphoma, liposarcoma, fibrosarcoma, and carcinosarcoma; colon cancers; rectal cancers; liver cancers such as but not limited to hepatocellular carcinoma and hepatoblastoma; gallbladder cancers such as adenocarcinoma; cholangiocarcinomas such as but not limited to papillary, nodular, and diffuse; lung cancers such as non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell carcinoma and small-cell lung cancer; testicular cancers such as but not limited to germinal tumor, seminoma, anaplastic, classic (typical), spermatocytic, nonseminoma, embryonal carcinoma, teratoma carcinoma, choriocarcinoma (yolk-sac tumor), prostate cancers such as but not limited to, prostatic intraepithelial neoplasia, adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; penal cancers; oral cancers such as but not limited to squamous cell carcinoma; basal cancers; salivary gland cancers such as but not limited to adenocarcinoma, mucoepidermoid carcinoma, and adenoidcystic carcinoma; pharynx cancers such as but not limited to squamous cell cancer, and verrucous; skin cancers such as but not limited to, basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, lentigo malignant melanoma, acral lentiginous melanoma; kidney cancers such as but not limited to renal cell carcinoma, adenocarcinoma, hypernephroma, fibrosarcoma, transitional cell cancer (renal pelvis and/or uterer); Wilms' tumor; bladder cancers such as but not limited to transitional cell carcinoma, squamous cell cancer, adenocarcinoma, carcinosarcoma. In addition, cancers include myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangioendotheliosarcoma, mesothelioma, synovioma, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma and papillary adenocarcinomas (for a review of such disorders, see Fishman et al., 1985, Medicine, 2d Ed., J.B. Lippincott Co., Philadelphia and Murphy et al., 1997, Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery, Viking Penguin, Penguin Books U.S.A., Inc., United States of America).

The EGFR binding protein or the EGFR targeting trispecific proteins of the disclosure are also useful in the treatment or prevention of a variety of cancers or other abnormal proliferative diseases, including (but not limited to) the following: carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid and skin; including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Burkitt's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyoscarcoma; other tumors, including melanoma, seminoma, tetratocarcinoma, neuroblastoma and glioma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma, and schwannomas; tumors of mesenchymal origin, including fibrosarcoma, rhabdomyoscarama, and osteosarcoma; and other tumors, including melanoma, xeroderma pigmentosum, keratoactanthoma, seminoma, thyroid follicular cancer and teratocarcinoma. It is also contemplated that cancers caused by aberrations in apoptosis would also be treated by the methods and compositions of the disclosure. Such cancers may include but not be limited to follicular lymphomas, carcinomas with p53 mutations, hormone dependent tumors of the breast, prostate and ovary, and precancerous lesions such as familial adenomatous polyposis, and myelodysplastic syndromes. In specific embodiments, malignancy or dysproliferative changes (such as metaplasias and dysplasias), or hyperproliferative disorders, are treated or prevented in the skin, lung, colon, breast, prostate, bladder, kidney, pancreas, ovary, or uterus. In other specific embodiments, sarcoma, melanoma, or leukemia is treated or prevented.

In some embodiments, the EGFR binding proteins or the EGFR targeting tri specific proteins of the present disclosure are administered to treat a neoplastic condition. Neoplastic conditions, in some embodiments, are benign or malignant; solid tumors or other blood neoplasia; and, in some embodiments, are selected from the group including, but not limited to: adrenal gland tumors, AIDS-associated cancers, alveolar soft part sarcoma, astrocytic tumors, autonomic ganglia tumors, bladder cancer (squamous cell carcinoma and transitional cell carcinoma), blastocoelic disorders, bone cancer (adamantinoma, aneurismal bone cysts, osteochondroma, osteosarcoma), brain and spinal cord cancers, metastatic brain tumors, breast cancer including triple negative breast cancer, carotid body tumors, cervical cancer, chondrosarcoma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, cutaneous benign fibrous histiocytomas, desmoplastic small round cell tumors, ependymomas, epithelial disorders, Ewing's tumors, extraskeletal myxoid chondrosarcoma, fibrogenesis imperfecta ossium, fibrous dysplasia of the bone, gallbladder and bile duct cancers, gastric cancer, gastrointestinal, gestational trophoblastic disease, germ cell tumors, glandular disorders, head and neck cancers, hypothalamic, intestinal cancer, islet cell tumors, Kaposi's Sarcoma, kidney cancer (nephroblastoma, papillary renal cell carcinoma), leukemias, lipoma/benign lipomatous tumors, liposarcoma/malignant lipomatous tumors, liver cancer (hepatoblastoma, hepatocellular carcinoma), lymphomas, lung cancers (small cell carcinoma, adenocarcinoma, squamous cell carcinoma, large cell carcinoma etc.), macrophagal disorders, medulloblastoma, melanoma, meningiomas, multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, neuroendocrine tumors, ovarian cancer, pancreatic cancers, papillary thyroid carcinomas, parathyroid tumors, pediatric cancers, peripheral nerve sheath tumors, phaeochromocytoma, pituitary tumors, prostate cancer, posterious unveal melanoma, rare hematologic disorders, renal metastatic cancer, rhabdoid tumor, rhabdomysarcoma, sarcomas, skin cancer, soft-tissue sarcomas, squamous cell cancer, stomach cancer, stromal disorders, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid metastatic cancer, and uterine cancers (carcinoma of the cervix, endometrial carcinoma, and leiomyoma).

In certain embodiments the EGFR binding proteins or the EGFR targeting trispecific proteins of the present disclosure are used as a front line therapy and administered to subjects who have not previously been treated for the cancerous condition. In other embodiments the EGFR binding proteins or the EGFR targeting trispecific proteins of the present disclosure are used to treat subjects that have previously been treated (with an EGFR binding protein or trispecific protein of this disclosure or with other anti-cancer agent) and have relapsed or determined to be refractory to the previous treatment. In some embodiments the EGFR binding proteins or the EGFR targeting trispecific proteins of the present disclosure are used to treat subjects that have recurrent tumors.

In some aspects, the EGFR binding proteins or the EGFR targeting trispecific proteins of the present disclosure are administered to treat a proliferative disorder comprising a solid tumor including, but not limited to, adrenal, liver, kidney, bladder, breast, gastric, ovarian, cervical, uterine, esophageal, colorectal, prostate, pancreatic, lung (both small cell and non-small cell), thyroid, carcinomas, sarcomas, glioblastomas and various head and neck tumors.

In some embodiments, the EGFR binding proteins or the EGFR targeting trispecific proteins of the present disclosure are administered to a subject suffering from melanoma. In some embodiments, the EGFR binding proteins or the EGFR targeting trispecific proteins of the present disclosure are used to diagnose, monitor, treat or prevent melanoma. The term “melanoma,” as used herein, includes all types of melanoma including, but not limited to, primary melanoma, malignant melanoma, cutaneous melanoma, extracutaneous melanoma, superficial spreading melanoma, polypoid melanoma, melanocarcinomas, melanoepitheliomas, melanosarcomas, melanoma in situ, nodular malignant melanoma, lentigo maligna melanoma, lentiginous melanoma, lentiginous malignant melanoma, mucosal lentiginous melanoma, mucosal melanoma, acral lentiginous melanoma, soft tissue melanoma, ocular melanoma, invasive melanoma, familial atypical mole and melanoma (FAM-M) syndrome, desmoplastic malignant melanoma or uveal melanoma.

EGFR is an effective tumor marker that is expressed on a number of different cancers and has been found to be associated with cancer stem cells. Thus, in some embodiments where the EGFR binding proteins or the EGFR targeting trispecific proteins of the disclosure are incorporated in a chimeric antigen receptor expressed on lymphocytes, the resulting “EGFR sensitized lymphocytes” (e.g., natural killer cells or T cells that immunospecifically recognize a EGFR determinant) are able to effectively mount an immune response directed to aberrant EGFR positive cells including cancer stem cells. This ability to effectively eliminate tumorigenic “seed” cells is often critical in reducing the possibility of tumor recurrence or metastasis. In some embodiments, such EGFR sensitized lymphocytes are used in combination with other therapeutic agents or as part of a maintenance regimen following standard of care treatments.

More generally a chimeric antigen receptor is an artificially constructed hybrid protein or polypeptide containing or comprising an antigen binding domain of an antibody linked to a signaling domain (e.g., T-cell signaling or T-cell activation domains). In some embodiments, CARs comprising the EGFR binding protein or the EGFR targeting trispecific proteins of the present disclosure have the ability to redirect the specificity and reactivity of sensitized lymphocytes (e.g., T-cells) toward EGFR positive target cells in a non-MHC-restricted manner by exploiting the antigen-binding properties of antibodies or antigen binding fragments thereof. The non-MHC-restricted antigen recognition gives T-cells expressing EGFR CARs the ability to recognize tumorigenic EGFR independent of antigen processing, thus bypassing a major mechanism of tumor escape. Moreover, when expressed in T-cells, CARs advantageously do not dimerize with endogenous T cell receptor (TCR) alpha and beta chains.

In selected aspects the EGFR binding proteins or the EGFR targeting trispecific proteins of the disclosure is incorporated into a chimeric antigen receptor (CAR) and the EGFR CAR is administered in a CAR based therapy effective at treating lung cancer, including the following subtypes: small cell lung cancer, non-small cell lung cancer (e.g., squamous cell non-small cell lung cancer or squamous cell small cell lung cancer) and large cell neuroendocrine carcinoma (LCNEC).

In some embodiments, the EGFR sensitive lymphocytes are administered to patients exhibiting limited stage disease or extensive stage disease. In other embodiments the disclosed EGFR binding proteins or the EGFR targeting trispecific proteins are administered to refractory patients (i.e., those whose disease recurs during or shortly after completing a course of initial therapy); sensitive patients (i.e., those whose relapse is longer than 2-3 months after primary therapy); or patients exhibiting resistance to a platinum based agent (e.g., carboplatin, cisplatin, oxaliplatin) and/or a taxane (e.g., docetaxel, paclitaxel, larotaxel or cabazitaxel). In another embodiment the disclosed EGFR CAR treatments are effective at treating ovarian cancer, including ovarian-serous carcinoma and ovarian-papillary serous carcinoma.

In another embodiment the EGFR binding proteins of the disclosure, the EGFR targeting trispecific proteins, the EGFR CAR, or the EGFR sensitized lymphocytes, or any combination thereof are used in maintenance therapy to reduce or eliminate the chance of tumor recurrence following the initial presentation of the disease. In some cases, the disorder has been treated and the initial tumor mass eliminated, reduced or otherwise ameliorated so the patient is asymptomatic or in remission. At such time the subject is administered pharmaceutically effective amounts of the disclosed the EGFR binding proteins of the disclosure, the EGFR targeting trispecific proteins, the EGFR CAR, or the EGFR sensitized lymphocytes, or any combination thereof one or more times regardless of if there is little or no indication of disease using standard diagnostic procedures. In some embodiments, the EGFR binding proteins or the EGFR targeting trispecific proteins of the disclosure, the EGFR CAR, or the EGFR sensitized lymphocytes, or any combination thereof is administered on a regular schedule over a period of time, such as weekly, every two weeks, monthly, every six weeks, every two months, every three months every six months or annually, for example, to reduce the potential of disease recurrence. Moreover such treatments are in some embodiments continued for a period of weeks, months, years or even indefinitely depending on the patient response and clinical and diagnostic parameters.

In yet another embodiment, the EGFR binding proteins or the EGFR targeting trispecific proteins of the disclosure, the EGFR CAR, or the EGFR sensitized lymphocytes, or any combination thereof are used to prophylactically or as an adjuvant therapy to prevent or reduce the possibility of tumor metastasis following a debulking procedure. As used in the present disclosure a “debulking procedure,” means any procedure, technique or method that eliminates, reduces, treats or ameliorates a tumor or tumor proliferation. Exemplary debulking procedures include, but are not limited to, surgery, radiation treatments (i.e., beam radiation), chemotherapy, immunotherapy or ablation. In some embodiments, at appropriate times, the EGFR binding proteins or the EGFR targeting trispecific proteins of the disclosure, the EGFR CAR, or the EGFR sensitized lymphocytes, or any combination thereof are administered as suggested by clinical, diagnostic or theranostic procedures to reduce tumor metastasis. In some embodiments, the dosing regimen is accompanied by appropriate diagnostic or monitoring techniques that allow it to be modified.

Yet other embodiments of the disclosure comprise administering the EGFR binding protein or the EGFR targeting trispecific proteins of the disclosure, the EGFR CAR, or the EGFR sensitized lymphocytes, or any combination thereof to subjects that are asymptomatic but at risk of developing a proliferative disorder. That is, in some embodiments, the EGFR binding protein or the EGFR targeting trispecific proteins of the disclosure, the EGFR CAR, or the EGFR sensitized lymphocytes, or any combination thereof are used in preventative sense and given to patients that have been examined or tested and have one or more noted risk factors (e.g., genomic indications, family history, in vivo or in vitro test results, etc.) but have not developed neoplasia. In such cases those skilled in the art would be able to determine an effective dosing regimen through empirical observation or through accepted clinical practices.

In some embodiments of the methods described herein, the EGFR binding proteins or the EGFR targeting trispecific proteins as described herein are administered in combination with an agent for treatment of the particular disease, disorder or condition. Agents include but are not limited to, therapies involving antibodies, small molecules (e.g., chemotherapeutics), hormones (steroidal, peptide, and the like), radiotherapies (γ-rays, X-rays, and/or the directed delivery of radioisotopes, microwaves, UV radiation and the like), gene therapies (e.g., antisense, retroviral therapy and the like) and other immunotherapies. In some embodiments, an EGFR targeting trispecific protein as described herein is administered in combination with anti-diarrheal agents, anti-emetic agents, analgesics, opioids and/or non-steroidal anti-inflammatory agents. In some embodiments, an EGFR binding proteins or an EGFR targeting trispecific protein as described herein is administered in combination with anti-cancer agents. Non-limiting examples of anti-cancer agents that can be used in the various embodiments of the disclosure, including pharmaceutical compositions and dosage forms and kits of the disclosure, include: acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cisplatin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; dactinomycin; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; docetaxel; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; ilmofosine; interleukin II (including recombinant interleukin II, or rIL2), interferon alpha-2a; interferon alpha-2b; interferon alpha-n1 interferon alpha-n3; interferon beta-I a; interferon gamma-I b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran; paclitaxel; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinzolidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride. Other examples of anti-cancer drugs include, but are not limited to: 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin; diphenyl spiromustine; docetaxel; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-I receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; HMG-CoA reductase inhibitor (such as but not limited to, Lovastatin, Pravastatin, Fluvastatin, Statin, Simvastatin, and Atorvastatin); loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel; paclitaxel analogues; paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen binding protein; sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; Vitaxin®; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer. Additional anti-cancer drugs are 5-fluorouracil and leucovorin. These two agents are particularly useful when used in methods employing thalidomide and a topoisomerase inhibitor. In some embodiments, an EGFR binding protein or an EGFR targeting trispecific protein of the present disclosure is used in combination with gemcitabine.

In some embodiments, the EGFR targeting trispecific protein as described herein is administered before, during, or after surgery.

Methods of Detection of EGFR Expression and Diagnosis of EGFR Associated Cancer

According to another embodiment of the disclosure, kits for detecting expression of EGFR in vitro or in vivo are provided. The kits include the foregoing EGFR targeting trispecific proteins (e.g., a trispecific protein containing a labeled anti-EGFR single domain antibody or antigen binding fragments thereof), and one or more compounds for detecting the label. In some embodiments, the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

In some cases, EGFR expression is detected in a biological sample. The sample can be any sample, including, but not limited to, tissue from biopsies, autopsies and pathology specimens. Biological samples also include sections of tissues, for example, frozen sections taken for histological purposes. Biological samples further include body fluids, such as blood, serum, plasma, sputum, spinal fluid or urine. A biological sample is typically obtained from a mammal, such as a human or non-human primate.

In one embodiment, provided is a method of determining if a subject has cancer by contacting a sample from the subject with an anti-EGFR binding protein (such as an anti-EGFR single domain antibody) as disclosed herein; and detecting binding of the single domain antibody to the sample. An increase in binding of the antibody to the sample as compared to binding of the antibody to a control sample identifies the subject as having cancer.

In another embodiment, provided is a method of confirming a diagnosis of cancer in a subject by contacting a sample from a subject diagnosed with cancer with an anti-EGFR single domain antibody as disclosed herein; and detecting binding of the antibody to the sample. An increase in binding of the antibody to the sample as compared to binding of the antibody to a control sample confirms the diagnosis of cancer in the subject.

In some examples of the disclosed methods, an EGFR single domain antibody of the trispecific protein is directly labeled.

In some examples, the methods further include contacting a second antibody that specifically binds the anti-EGFR single domain antibody with the sample; and detecting the binding of the second antibody. An increase in binding of the second antibody to the sample as compared to binding of the second antibody to a control sample detects cancer in the subject or confirms the diagnosis of cancer in the subject.

In some cases, the cancer is mesothelioma, prostate cancer, lung cancer, stomach cancer, squamous cell carcinoma, pancreatic cancer, cholangiocarcinoma, triple negative breast cancer or ovarian cancer, or any other type of cancer that expresses EGFR.

In some examples, the control sample is a sample from a subject without cancer. In particular examples, the sample is a blood or tissue sample.

In some cases, the antibody that binds (for example specifically binds) EGFR is directly labeled with a detectable label. In another embodiment, the antibody that binds (for example, specifically binds) EGFR (the first antibody) is unlabeled and a second antibody or other molecule that can bind the antibody that specifically binds EGFR is labeled. A second antibody is chosen such that it is able to specifically bind the specific species and class of the first antibody. For example, if the first antibody is a llama IgG, then the secondary antibody may be an anti-llama-IgG. Other molecules that can bind to antibodies include, without limitation, Protein A and Protein G, both of which are available commercially. Suitable labels for the antibody or secondary antibody are described above, and include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, magnetic agents and radioactive materials. Non-limiting examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase. Non-limiting examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin. Non-limiting examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin. A non-limiting exemplary luminescent material is luminol; a non-limiting exemplary a magnetic agent is gadolinium, and non-limiting exemplary radioactive labels include 125I, 131I, 35S or 3H.

In an alternative embodiment, EGFR can be assayed in a biological sample by a competition immunoassay utilizing EGFR standards labeled with a detectable substance and an unlabeled antibody that specifically binds EGFR. In this assay, the biological sample, the labeled EGFR standards and the antibody that specifically bind EGFR are combined and the amount of labeled EGFR standard bound to the unlabeled antibody is determined. The amount of EGFR in the biological sample is inversely proportional to the amount of labeled EGFR standard bound to the antibody that specifically binds EGFR.

The immunoassays and method disclosed herein can be used for a number of purposes. In one embodiment, an antibody that specifically binds EGFR may be used to detect the production of EGFR in cells in cell culture. In another embodiment, the antibody can be used to detect the amount of EGFR in a biological sample, such as a tissue sample, or a blood or serum sample. In some examples, the EGFR is cell-surface EGFR. In other examples, the EGFR is soluble EGFR (e.g., EGFR in a cell culture supernatant or soluble EGFR in a body fluid sample, such as a blood or serum sample).

In one embodiment, a kit is provided for detecting EGFR in a biological sample, such as a blood sample or tissue sample. For example, to confirm a cancer diagnosis in a subject, a biopsy can be performed to obtain a tissue sample for histological examination. Alternatively, a blood sample can be obtained to detect the presence of soluble EGFR protein or fragment. Kits for detecting a polypeptide will typically comprise a single domain antibody, according to the present disclosure, that specifically binds EGFR. In some embodiments, an antibody fragment, such as an scFv fragment, a VH domain, or a Fab is included in the kit. In a further embodiment, the antibody is labeled (for example, with a fluorescent, radioactive, or an enzymatic label).

In one embodiment, a kit includes instructional materials disclosing means of use of an antibody that binds EGFR (such as an EGFR binding protein or an EGFR targeting trispecific protein). The instructional materials may be written, in an electronic form (such as a computer diskette or compact disk), may be visual (such as video files), or provided through an electronic network, for example, over the internet, World Wide Web, an intranet, or other network. The kits may also include additional components to facilitate the particular application for which the kit is designed. Thus, for example, the kit may additionally contain means of detecting a label (such as enzyme substrates for enzymatic labels, filter sets to detect fluorescent labels, appropriate secondary labels such as a secondary antibody, or the like). The kits may additionally include buffers and other reagents routinely used for the practice of a particular method. Such kits and appropriate contents are well known to those of skill in the art.

In one embodiment, the diagnostic kit comprises an immunoassay. Although the details of the immunoassays may vary with the particular format employed, the method of detecting EGFR in a biological sample generally includes the steps of contacting the biological sample with an antibody which specifically reacts, under immunologically reactive conditions, to a EGFR polypeptide. The antibody is allowed to specifically bind under immunologically reactive conditions to form an immune complex, and the presence of the immune complex (bound antibody) is detected directly or indirectly.

Methods of determining the presence or absence of a cell surface marker are well known in the art. For example, the antibodies can be conjugated to other compounds including, but not limited to, enzymes, magnetic beads, colloidal magnetic beads, haptens, fluorochromes, metal compounds, radioactive compounds or drugs. The antibodies can also be utilized in immunoassays such as but not limited to radioimmunoassays (RIAs), ELISA, or immunohistochemical assays. The antibodies can also be used for fluorescence activated cell sorting (FACS). FACS employs a plurality of color channels, low angle and obtuse light-scattering detection channels, and impedance channels, among other more sophisticated levels of detection, to separate or sort cells (see U.S. Pat. No. 5,061,620). Any of the single domain antibodies that bind EGFR, as disclosed herein, can be used in these assays. Thus, the antibodies can be used in a conventional immunoassay, including, without limitation, an ELISA, an RIA, FACS, tissue immunohistochemistry, Western blot or imunoprecipitation.

EXAMPLES Example 1: Screening of Phage Display Library for Identification of EGFR Binding

Domains

Llamas were immunized with purified EGFR protein expressed in 293 cells. A phage display library for expression of heavy chain variable antibody domains was constructed from circulating B cells (seevan der Linden, de Geus, Stok, Bos, van Wassenaar, Verrips, and Frenken. 2000. J Immunol Methods 240:185-195). Phage clones were screening for binding to EGFR by expressing the clones in E. coli, preparing periplasmic extracts, and screening the clones for EGFR binding activity by ELISA. Thirty-eight unique heavy chain only sequences were identified that produced a signal in the ELISA screening (SEQ ID Nos. 1 to 38). The CDR1, CDR2, and CDR3 sequences for these heavy variable domains were, respectively, SEQ ID Nos. 50 to 87, SEQ ID Nos. 99 to 136, and SEQ ID Nos. 148 to 185.

Example 2: Humanization of EGFR Binding Heavy Chain Only Single Domain Antibodies and T Cell Dependent Cellular Cytotoxicity Assay

Eleven llama anti-EGFR heavy chain only single domain antibodies from Example 1 were humanized (SEQ ID Nos. 39 to 49). The CDR1, CDR2, and CDR3 sequences for these heavy variable domains are, respectively, SEQ ID Nos. 88 to 98, SEQ ID Nos. 137 to 147, and SEQ ID Nos. 186 to 196.

The 11 humanized anti-EGFR sequences, along with their 11 parental llama anti-EGFR sequences, were cloned into trispecific (also referred to herein as TriTAC™) expression constructs with a signal domain followed by an anti-EGFR domain followed by a GGGGSGGGS (SEQ ID No. 246) linker followed by anti-human albumin single domain antibody 10G (SEQ ID No. 210) followed by a GGGGSGGGS (SEQ ID No. 246) linker followed by anti-human CD3 antibody 2B2 (SEQ ID No. 229) followed by a HHHHHH (SEQ ID No. 247) tag.

The anti-EGFR TriTAC™ constructs were transfected into EXPI293™ cells. These anti-EGFR TriTAC™ proteins were engineered with a protein A binding site, and the amount of anti-EGFR TriTAC™ protein in the conditioned media from the transfected EXPI293™ cells was quantitated by using an Octet instrument with protein A tips using a TriTAC™ protein of similar molecular weight to the EGFR TriTAC™ proteins as a standard.

The conditioned media were tested in a T-cell dependent cellular cytotoxicity assay (see Nazarian A A, Archibeque I L, Nguyen Y H, Wang P, Sinclair A M, Powers D A. 2015. J Biomol Screen. 20:519-27). In this assay, luciferase labelled HCT116 cells were combined with purified human T cells and a titration of EGFR TriTAC™ proteins. The titration was based on the quantitation described in the previous paragraph. If an EGFR TriTAC™ protein directs T cells to kill the EGFR-expression HCT116 cells, then the viability of the HCT116 cells, as determined by running a luciferase assay at 48 hours after starting the experiment, was expected to decrease. The results are shown in FIGS. 2-5, which provide have graphs of representative TDCC data, and EC₅₀ values from the TDCC assay are listed in Table 1. The EGFR TriTAC™ proteins with TDCC activity had EC₅₀ values ranging from 6.3 pM to 183 nM. In some cases, the humanized version of a binder did not have activity whereas the llama binder did have activity, as exemplified by the comparison of EL16 and EL18 to EH16 and EH18. It is contemplated that the lack of activity could signify that the humanization process requires refinement to generate a humanized molecule with TDCC activity similar to the parental llama sequence. In some cases, neither the llama nor the equivalent humanized EGFR binder had activity in the TDCC assay. It is contemplated that this lack of activity does not conclusively show these binders lack TDCC activity but could be caused by a different complication, for example, differential glycosylation of EGFR in HCT116 cells. A negative control for the TDCC assays was a TriTAC™ protein targeting GFP (FIG. 5), which did not direct the T cells to kills the HCT116 cells.

TABLE 1 Activity of Anti-EGFR TriTAC ™ molecules in DMS153 TDCC Assays. EGFR binder K_(D) (M) EL1 n/d EL4 6.82E−11 EL16 2.33E−10 EL18 1.69E−10 EL38 n/d EL44 n/d EL60 n/d EL64 n/d EL77 n/d EL104 6.33E−12 EL113 8.23E−11 EH1 n/d EH4 1.83E−10 EH16 n/d EH18 n/d EH38 n/d EH44 n/d EH60 n/d EH64 n/d EH77 n/d EH104 7.15E−12 EH113 n/d n/d means an EC₅₀ value was not possible to determine with these assay data.

Using the same conditioned media used in the TDCC assay, the binding affinities of the anti-EGFR TriTAC™ molecules for human, cynomolgus, and mouse EGFR proteins were measured using biotinylated EGFR proteins and an Octet instrument with streptavidin tips. The K_(D) measurements were made using a single 80 nM concentration of TriTAC™ protein, which allowed for rank ordering potency. These measured relative affinities are listed in Table 2. Some TriTAC™ proteins did not bind the biotinylated immobilized EGFR in this assay, but other bound with Kd values ranging from 4 nM to 112 nM for human EGFR, 4 nM to 92 nM for cynomolgus EGFR, and 16 nM to 63 nM for mouse EGFR. It is contemplated that lack of binding in this assay could happen because, for example, biotinylation of EGFR could have happened at a recognition site of an anti-EGFR binder, and thus lack of binding does not demonstrate a molecule is unable to bind EGFR.

TABLE 2 Binding Affinities of Anti-EGFR TriTAC ™ molecules for Human, Cynomolgus, and Mouse EGFR Protein. K_(D) human K_(D) cynomolgus K_(D) mouse EGFR binder EGFR (nM) EGFR (nM) EGFR (nM) EL4 54 59 49 EL16 112 73 n/b EL18 49 44 63 EL104 4 4 13 EL113 15 15 59 EH4 61 70 59 EH104 5 6 16 EH113 93 92 l/b l/b means low binding and a K_(D) value could not be calculated, n/b means no binding with detected in this assay.

Example 3: An Exemplary Anti-EGFR TriTAC™ Directs T Cells to Kill EGFR Expressing Ovarian Cancer Cells

A human T-cell dependent cellular cytotoxicity (TDCC) assay is used to measure the ability of T cell engagers, including trispecific molecules, to direct T cells to kill tumor cells (see Nazarian et al. 2015. J Biomol Screen. 20:519-27). The Caov3 cells used in this assay are engineered to express luciferase. T cells from 5 different healthy and target cancer cells Caov3 are mixed together and varying amounts of an exemplary EGFR targeting trispecific molecule of this disclosure is added and the mixture is incubated for 48 hours at 37° C. Caov3 cells and T cells are also incubated for 48 hours at 37° C. with a control trispecific molecule which targets GFP. After 48 hours, the remaining viable tumor cells are quantified by a luminescence assay.

It is observed that the exemplary anti-EGFR TriTAC™ molecule is able to direct the T cells from all 5 healthy donors to kill the target cancer cells Caov3, whereas the control TriTAC™ molecule is not able to direct the T cells from any of the 5 health donors to kill the Caov3 cells.

Example 4: Xenograft Tumor Model

An EGFR targeting trispecific protein of this disclosure is evaluated in a xenograft model. In order to determine efficacy of the exemplary EGFR targeting trispecific molecule in vivo, multiple xenograft tumor models are used. Examples of common tumor cell lines for use in xenograft tumor studies include A549 (non-small cell lung carcinoma) cells, DU-145 (prostate) cells, MCF-7 (breast) cells, Colo 205 (colon) cells, 3T3/]GF-IR (mouse fibroblast) cells, NCI H441 cells, HEP G2 (hepatoma) cells, MDA MB 231 (breast) cells, HT-29 (colon) cells, MDA-MB-435s (breast) cells, U266 cells, SH-SYSY cells, Sk-Mel-2 cells, NCI-H929, RPM18226, and A431 cells. Immune-deficient NOD/scid mice are sub-lethally irradiated (2 Gy) and subcutaneously inoculated with 1×10⁶ tumor cells (e.g., NCI H441 cells) into their right dorsal flank. When tumors reach 100 to 200 mm³, animals are allocated into 3 treatment groups. Groups 2 and 3 are intraperitoneally injected with 1.5×10⁷ activated human T-cells. Three days later, animals from Group 3 are subsequently treated with the exemplary EGFR targeting trispecific antigen-binding protein of. Groups 1 and 2 are only treated with vehicle. Body weight and tumor volume are determined for 30 days, beginning at least 5 days post treatment with the exemplary EGFR targeting trispecific protein.

It is expected that animals treated with the exemplary EGFR targeting trispecific protein have a statistically significant delay in tumor growth in comparison to the respective vehicle-treated control group.

Example 5: Proof-of-Concept Clinical Trial Protocol for Administration of the EGFR Trispecific Antigen-Binding Protein of Example 1 to Ovarian Cancer Patients

This is a Phase I/II clinical trial for studying an exemplary EGFR trispecific antigen-binding protein of this disclosure as a treatment for triple negative breast cancer.

Study Outcomes:

Primary:

Maximum tolerated dose of the exemplary EGFR targeting trispecific protein.

Secondary:

To determine whether in vitro response of the exemplary EGFR targeting trispecific proteinis associated with clinical response

Phase I

The maximum tolerated dose (MTD) will be determined in the phase I section of the trial.

-   -   1.1 The maximum tolerated dose (MTD) will be determined in the         phase I section of the trial.     -   1.2 Patients who fulfill eligibility criteria will be entered         into the trial to EGFR targeting trispecific proteins of the         previous examples.     -   1.3 The goal is to identify the highest dose of EGFR targeting         trispecific proteins of the previous examples that can be         administered safely without severe or unmanageable side effects         in participants. The dose given will depend on the number of         participants who have been enrolled in the study prior and how         well the dose was tolerated. Not all participants will receive         the same dose.

Phase II

-   -   2.1 A subsequent phase II section will be treated at the MTD         with a goal of determining if therapy with therapy of the         exemplary EGFR targeting trispecific protein results in at least         a 20% response rate.     -   Primary Outcome for the Phase II—To determine if therapy of EGFR         targeting trispecific protein results in at least 20% of         patients achieving a clinical response (blast response, minor         response, partial response, or complete response)

Eligibility:

Histologically confirmed triple negative breast cancer, showing at least one of the following:

-   -   High grade or metaplastic morphology, may have medullary         features;     -   Geographic necrosis, pushing borders, stromal lymphocytic         response, increased mitotic count;     -   Secretory breast carcinomas with ETV6-NTRK3 fusion gene solid         growth pattern, high nuclear grade, marked lymphocytic         infiltrate and geographic necrosis.

While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

SEQ. ID NO. Name Sequence  1 EL1 QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELVATSTRDGNVD YAESVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNADLRTAVDLIRANYWGQGTQ VTVSS  2 EL104 QVQLQESGGGLVQAGDSLRLSCVVSGRTDSWYVMGWFRQAPGKDREFVAGVSWSYGNT YYADSVKGRFTASRDNAKNTAYLQMNSLNAEDTAVYYCAARVSREVIPTRWDLYNYWG QGTQVTVSS  3 EL106 QVQLQESGGGSVQPGGSLRVSCVVSRTIISINAMTWYHQAPGKRRELVAIITSGGETN YADSVKGRFTISRDNAKNTAYLQMNNLKPEDTGVYYCNVVPPLGSWGQGTQVTVSS  4 EL113 QVQLQESGGGRVQAGGSLRLSCSASARTLRLYAVGWFRQAPGKEREFVAGIGRSERTY YTDSVKGRFTLSRDNAKNTVFLEMNDLEPEDTAVYFCALTFQTTDMVDVPTTQHEYDY WGRGTQVTVSS  5 EL12 QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELVATSTHDGNTD YADSVKGRFTISRDNVKNTVYLQMNSLKPEDTAVYYCNADLRTAVDLIRANYWGQGTQ VTVSS  6 EL120 QVQLQESGGGLVQPGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELVATSTRDGNTD YADSVKGRFTISRDNAKDTVYLQMNSLKPEDTAVYYCNADLRTAVDLIRANYWGQGTQ VTVSS  7 EL133 QVQLQESGGGLVQAGGSLTLSCAASGRYQMAWFRQAPEKEREFVGTISSGDSTWYTNS VKGRFAISRDSARNTVYLQMNDLKPEDTAIYYCAAALYYRDSRRAADYPYWGQGTQVT VSS  8 EL138 QVQLQESGGGRVQAGESLRLSCSTSTRTLKLYAVGWFRQAPGKERDFVAGIGRSERIY YIDSVKGRFTLSRDNAKNTVFLEMNDLEPEDTAVYFCAATFQTSDNVGVPTVQHEYDY WGQGTQVTVSS  9 EL147 QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELVATSTHDGNTD YADSVKGRFTISRDNAKNTVTLQMNSLKPEDTAVYYCNADLRTAVDLIRANYWGQGTQ VTVSS 10 EL148 QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELVATFTRDGNTD YADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNTDLRTAVDLIRANYWGQGTQ VTVSS 11 EL15 QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELVATSTHDGNTD YADSLKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNADLRTAVDLIRANYWGQGTQ VTVSS 12 EL153 QVQLQESGGGSVQAGGSLRLSCAASGRYQMAWFRQAPEKEREFVGTISSGDSTWYTNS LKGRFAISRDSARDTVYLQMNDLKPEDTAVYYCAAALYYRDSRRAADYPYWGQGTQVT VSS 13 EL16 QVQLQESGGGLVQTGGSLRLSCAVSGSIVTINAMTWYRQAPGKRRELVAIITSGGETN YADSVKGRFTISRDNAKNTAHLQMNSLNPEDTGVYYCNVVPPLGSWGQGTQVTVSS 14 EL162 QVQLQESGGGLVQTGGSLRLSCAVSRSIVSIKSMTWYRQAPGKRRELVALITSGGETN YSDSVKGRFTISRDNAKNTVYLQMNSLKPEDTGVYYCNVVPPLGSWGQGTQVTVSS 15 EL165 QVQLQESGGGLVETGGSLRLSCAGSGSTFRHHAMAWFRQTPGKEREFVSAINDHGDRT KYLDSVRGRFTISRDNTDNMVYLQMTDLRPEDTANYSCAAGPLVDYLETTPLVYTYWG HGTQVTVSS 16 EL17 QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELVATSTHDGNTD YADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNADLRTAVDLIRANYWGQGTQ VTVSS 17 EL171 QVQLQESGGGSVQAGGSLTLSCAASGSIAYIYTMDWYRQAPGKQRELVATSTHDGNTD YADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNADLRTAVDLIRANYWGQGTQ VTVSS 18 EL172 QVQLQESGGGLVQPGGSLRLSCTASVSIFSVNAVDWYRQSPGKERELVAIMTSDGSTN YGDSVKGRFTISRDNAKNTVYLQMNNLKPEDTAVYYCNTVPPRYWGQGTQVTVSS 19 EL176 QVQLQESGGGLVQPGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELVATSTRDGNID YADSVKGRFTISRDSAKNTVYLQMSSLKPEDTAVYYCNADLRTAVDLIRANYWGQGTQ VTVSS 20 EL178 QVQLQESGGGLVQAGGSLTLSCAASGRYQLAWFRQAPEKVREFVGTISSGDSTWYTNS VKGRFAISRDSARNTVYLQMNDLKPEDTAVYYCAAALYYRDSRRAADYPYWGQGTQVT VSS 21 EL18 QVQLQESGGGSVQAGGSLRLSCAASGRYHMAWFRQAPEKEREFVGTISSGDSTWYTNS VKGRFAISRDSARNTAYLQMNDLKPEDTAVYYCAAALYYGDSRRAADYPYWGQGTQVT VSS 22 EL187 QVQLQESGGGSVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELVATSTHDGNTD YTDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNADLRTAVDLIRANYWGQGTQ VTVSS 23 EL27 QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQTPGKQRELVATSTRDANTD YAGSVKGRFTISRDNAKDTVYLQMNSLKPEDTAVYYCHADLRTAVDLIRANYWGQGTQ VTVSS 24 EL30 QVQLQESGGGLVQAGGSLRLSCAASGRYNMAWFRQAPEKEREFVGTITSADSTWYTNS VKGRFAITQDSARNTVYLQMNDLKPEDTAVYYCAAALYYGDSRRAADYPYWGQGTQVT VSS 25 EL33 QVQLQESGGGLVQPGGSLRLSCAASGRYQMAWFRQAPEKEREFVGTISSGDSTWYTNS VKGRFAISRDSARTTVYLQMNDLKPEDTAVYYCAAALYYRDSWRAADYPYWGQGTQVT VSS 26 EL35 QVQLQESGGGLVQPGESLRLSCAATGRYHLAWFRQAPEKEREFVGTITSADSTWYTNS VKGRFAITRDSARNTVYLQMNDLKPEDTAVYYCAAALYYGDSRRAADYPYWGQGTQVT VSS 27 EL4 QVQLQESGGGLVQAGGSLKLSCADSGRSFSNYIMGWFRQAPGKEREFVAGLGWSPGNT YYADSVKGRFTISRDNAKNMVYLQMNSLNPEDTAVYYCAARRGDVIYTTPWNYVYWGQ GTQVTVSS 28 EL40 QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELVATSTHDGNTD YADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNADLRTPVDLIRANYWGQGTQ VTVSS 29 EL43 QVQLQESGGGSVQAGGSLRLSCAAPGRYQMAWFRQAPEKEREFVGTISSGDSTWYTNS VKGRFAISRDSARNTVYLQMNDLKSEDTAVYYCAAALYYRDSRRAIDYPYWGQGTQVT VSS 30 EL44 QVQLQESGGGSVQAGGSLRLSCAASGLTFSSYAMAWFRQAPGKQRELVARITSGGTTD YADSVKGRFTISRDNAKNTMYLQMNSLKPEDTAVYYCAADLTYRNLLLKLPHYWGQGT QVTVSS 31 EL51 QVQLQESGGGLVQAGGSLRLSCAASGNIAYIYTMDWYRQAPGKQRELVATSTHDGSTD YADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNADLRTPVDLIRANYWGQGTQ VTVSS 32 EL56 QVQLQESGGGLVQPGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELVATSTWDGNTD YADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNADLRTAVDLIRANYWGQGTQ VTVSS 33 EL6 QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELVATSTHDGNTD YADSVKGRFTISRDNAKNTVYLQMSSLKPDDTAVYYCNADLRTAVDLIRANYWGQGTQ VTVSS 34 EL64 QVQLQESGGGLVQAGESLSLSCAASGNDFVITDMHWYRQAPGKQREWVATITRFATTN YADSVKGRFTISRDNAKNTWYLQMNSLKPDDTAVYYCKAIGLRGVPDVNRQFEVWGQG TQVTVSS 35 EL77 QVQLQESGGGLVQAGGSLRLSCAASGAIAYIYGMGWYRQAPGNQRELVAAISSGGSTD YADSVKGRFTISRDNAKNTVYLQMSSLKPEDTAVYYCNADVRTSRNLVRSDYWGQGTQ VTVSS 36 EL79 QVQLQESGGGLVQAGGSLRLSCAASGRYHTAWFRQAPEKEREFVGTISSGDSTWYTNS VKGRFAISRDSARNTVYLQMNDLKPEDTAVYYCAAALYYGDSRRAGDYPYWGQGTQVT VSS 37 EL83 QVQLQESGGGLVQAGGSLRLSCAASGNIAYIYTMNWYRQAPGKQRELVATSTHAGNTD YADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCNVDLRTAVDLIRANYWGQGTQ VTVSS 38 EL88 QVQLQESGGGLVQPGGSLRLSCAASGNIAYIYTMGWYRQAPGKQRELVATSTHDGNSD YADSVKGRFTISRDNAKNTVYLQMNTLKPDDTAVYYCNADLRTPVDRIRGNFWGQGTQ VTVSS 39 EH1 EVQLLESGGGLVQPGGSLTLSCAASGSIAYIYTMDWYRQAPGKQRELVATSTRDGNVD YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCNADLRTAVDLIRANYWGLGTQ VTVSS 40 EH104 EVQLLESGGGLVQPGGSLTLSCAASGRTDSWYVMGWFRQAPGKDREFVAGVSWSYGNT YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAARVSREVIPTRWDLYNYWG LGTQVTVSS 41 EH113 EVQLLESGGGLVQPGGSLTLSCAASARTLRLYAVGWFRQAPGKEREFVAGIGRSERTY YTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCALTFQTTDMVDVPTTQHEYDY WGLGTQVTVSS 42 EH16 EVQLLESGGGLVQPGGSLTLSCAASGSIVTINAMTWYRQAPGKRRELVAIITSGGETN YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCNVVPPLGSWGLGTQVTVSS 43 EH18 EVQLLESGGGLVQPGGSLTLSCAASGRYHMAWFRQAPGKEREFVGTISSGDSTWYTNS VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAALYYGDSRRAADYPYWGLGTQVT VSS 44 EH38 EVQLLESGGGLVQPGGSLTLSCAASGSTFRHHAMAWFRQTPGKEREFVSAINDHGDRT KYLDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAGPLVDYLETTPLVYTYWG LGTQVTVSS 45 EH4 EVQLLESGGGLVQPGGSLTLSCAASGRSFSNYIMGWFRQAPGKEREFVAGLGWSPGNT YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAARRGDVIYTTPWNYVYWGL GTQVTVSS 46 EH44 EVQLLESGGGLVQPGGSLTLSCAASGLTFSSYAMAWFRQAPGKQRELVARITSGGTTD YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAADLTYRNLLLKLPHYWGLGT QVTVSS 47 EH60 EVQLLESGGGLVQPGGSLTLSCAASVSIFSVNAVDWYRQSPGKERELVAIMTSDGSTN YDDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCNTVPPRYWGLGTQVTVSS 48 EH64 EVQLLESGGGLVQPGGSLTLSCAASGNDFVITDMHWYRQAPGKQREWVATITRFATTN YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKAIGLRGVPDVNRQFEVWGLG TQVTVSS 49 EH77 EVQLLESGGGLVQPGGSLTLSCAASGAIAYIYGMGWYRQAPGKQRELVAAISSGGSTD YADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCNADVRTSRNLVRSDYWGLGTQ VTVSS

SEQ. CDR1 ID NO. Name Sequence 50 EL1 GSIAYIYTMD 51 EL104 GRTDSWYVMG 52 EL106 RTIISINAMT 53 EL113 ARTLRLYAVG 54 EL12 GSIAYIYTMD 55 EL120 GSIAYIYTMD 56 EL133 GRYQMA 57 EL138 TRTLKLYAVG 58 EL147 GSIAYIYTMD 59 EL148 GSIAYIYTMD 60 EL15 GSIAYIYTMD 61 EL153 GRYQMA 62 EL16 GSIVTINAMT 63 EL162 RSIVSIKSMT 64 EL165 GSTFRHHAMA 65 EL17 GSIAYIYTMD 66 EL171 GSIAYIYTMD 67 EL172 VSIFSVNAVD 68 EL176 GSIAYIYTMD 69 EL178 GRYQLA 70 EL18 GRYHMA 71 EL187 GSIAYIYTMD 72 EL27 GSIAYIYTMD 73 EL30 GRYNMA 74 EL33 GRYQMA 75 EL35 GRYHLA 76 EL4 GRSFSNYIMG 77 EL40 GSIAYIYTMD 78 EL43 GRYQMA 79 EL44 GLTFSSYAMA 80 EL51 GNIAYIYTMD 81 EL56 GSIAYIYTMD 82 EL6 GSIAYIYTMD 83 EL64 GNDFVITDMH 84 EL77 GAIAYIYGMG 85 EL79 GRYHTA 86 EL83 GNIAYIYTMN 87 EL88 GNIAYIYTMG 88 EH1 GSIAYIYTMD 89 EH104 GRTDSWYVMG 90 EH113 ARTLRLYAVG 91 EH16 GSIVTINAMT 92 EH18 GRYHMA 93 EH38 GSTFRHHAMA 94 EH4 GRSFSNYIMG 95 EH44 GLTFSSYAMA 96 EH60 VSIFSVNAVD 97 EH64 GNDFVITDMH 98 EH77 GAIAYIYGMG

SEQ. ID NO. Name CDR2 Sequence  99 EL1 TSTRDGNVDYAESVKG 100 EL104 VSWSYGNTYYADSVKG 101 EL106 IITSGGETNYADSVKG 102 EL113 GIGRSERTYYTDSVKG 103 EL12 TSTHDGNTDYADSVKG 104 EL120 TSTRDGNTDYADSVKG 105 EL133 TISSGDSTWYTNSVKG 106 EL138 GIGRSERIYYIDSVKG 107 EL147 TSTHDGNTDYADSVKG 108 EL148 TFTRDGNTDYADSVKG 109 EL15 TSTHDGNTDYADSLKG 110 EL153 TISSGDSTWYTNSLKG 111 EL16 IITSGGETNYADSVKG 112 EL162 LITSGGETNYSDSVKG 113 EL165 AINDHGDRTKYLDSVRG 114 EL17 TSTHDGNTDYADSVKG 115 EL171 TSTHDGNTDYADSVKG 116 EL172 IMTSDGSTNYGDSVKG 117 EL176 TSTRDGNIDYADSVKG 118 EL178 TISSGDSTWYTNSVKG 119 EL18 TISSGDSTWYTNSVKG 120 EL187 TSTHDGNTDYTDSVKG 121 EL27 TSTRDANTDYAGSVKG 122 EL30 TITSADSTWYTNSVKG 123 EL33 TISSGDSTWYTNSVKG 124 EL35 TITSADSTWYTNSVKG 125 EL4 GLGWSPGNTYYADSVKG 126 EL40 TSTHDGNTDYADSVKG 127 EL43 TISSGDSTWYTNSVKG 128 EL44 RITSGGTTDYADSVKG 129 EL51 TSTHDGSTDYADSVKG 130 EL56 TSTWDGNTDYADSVKG 131 EL6 TSTHDGNTDYADSVKG 132 EL64 TITRFATTNYADSVKG 133 EL77 AISSGGSTDYADSVKG 134 EL79 TISSGDSTWYTNSVKG 135 EL83 TSTHAGNTDYADSVKG 136 EL88 TSTHDGNSDYADSVKG 137 EH1 TSTRDGNVDYADSVKG 138 EH104 GVSWSYGNTYYADSVKG 139 EH113 GIGRSERTYYTDSVKG 140 EH16 IITSGGETNYADSVKG 141 EH18 TISSGDSTWYTNSVKG 142 EH38 AINDHGDRTKYLDSVKG 143 EH4 GLGWSPGNTYYADSVKG 144 EH44 RITSGGTTDYADSVKG 145 EH60 IMTSDGSTNYDDSVKG 146 EH64 TITRFATTNYADSVKG 147 EH77 AISSGGSTDYADSVKG

SEQ. ID NO. Name CDR3 Sequence 148 EL1 DLRTAVDLIRANY 149 EL104 RVSREVIPTRWDLYNY 150 EL106 VPPLGS 151 EL113 TFQTTDMVDVPTTQHEYDY 152 EL12 DLRTAVDLIRANY 153 EL120 DLRTAVDLIRANY 154 EL133 ALYYRDSRRAADYPY 155 EL138 TFQTSDNVGVPTVQHEYDY 156 EL147 DLRTAVDLIRANY 157 EL148 DLRTAVDLIRANY 158 EL15 DLRTAVDLIRANY 159 EL153 ALYYRDSRRAADYPY 160 EL16 VPPLGS 161 EL162 VPPLGS 162 EL165 GPLVDYLETTPLVYTY 163 EL17 DLRTAVDLIRANY 164 EL171 DLRTAVDLIRANY 165 EL172 VPPRY 166 EL176 DLRTAVDLIRANY 167 EL178 ALYYRDSRRAADYPY 168 EL18 ALYYGDSRRAADYPY 169 EL187 DLRTAVDLIRANY 170 EL27 DLRTAVDLIRANY 171 EL30 ALYYGDSRRAADYPY 172 EL33 ALYYRDSWRAADYPY 173 EL35 ALYYGDSRRAADYPY 174 EL4 RRGDVIYTTPWNYVY 175 EL40 DLRTPVDLIRANY 176 EL43 ALYYRDSRRAIDYPY 177 EL44 DLTYRNLLLKLPHY 178 EL51 DLRTPVDLIRANY 179 EL56 DLRTAVDLIRANY 180 EL6 DLRTAVDLIRANY 181 EL64 IGLRGVPDVNRQFEV 182 EL77 DVRTSRNLVRSDY 183 EL79 ALYYGDSRRAGDYPY 184 EL83 DLRTAVDLIRANY 185 EL88 DLRTPVDRIRGNF 186 EH1 DLRTAVDLIRANY 187 EH104 RVSREVIPTRWDLYNY 188 EH113 TFQTTDMVDVPTTQHEYDY 189 EH16 VPPIGS 190 EH18 ALYYGDSRRAADYPY 191 EH38 GPLVDYLETTPLVYTY 192 EH4 RRGDVIYTTPWNYVY 193 EH44 DLTYRNLLLKLPHY 194 EH60 VPPRY 195 EH64 IGLRGVPDVNRQFEV 196 EH77 DVRTSRNLVRSDY

SEQ ID NO: Description AA Sequence 197 Linker (GS)_(n) 198 Linker (GGS)_(n) 199 Linker (GGGS)_(n) 200 Linker (GGSG)_(n) 201 Linker (GGSGG)_(n) 202 Linker (GGGGS)_(n) 203 Linker (GGGGG)_(n) 204 Linker (GGG)_(n)

SEQ ID NO: Description AA Sequence 205 Anti-HSA sdAb clone EVQLVESGGGLVQPGNSLRLSCAASGFTFSRFGMSWVRQAPGKGLEWVSS 6C ISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGG SLSRSSQGTLVTVSS 206 Anti-HSA sdAb clone EVQLVESGGGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSS 7A ISGSGADTLYADSLKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGG SLSKSSQGTLVTVSS 207 Anti-HSA sdAb clone EVQLVESGGGLVQPGNSLRLSCAASGFTYSSFGMSWVRQAPGKGLEWVSS 7G ISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGG SLSKSSQGTLVTVSS 208 Anti-HSA sdAb clone EVQLVESGGGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSS 8H ISGSGTDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGG SLSRSSQGTLVTVSS 209 Anti-HSA sdAb clone EVQLVESGGGLVQPGNSLRLSCAASGFTFSRFGMSWVRQAPGKGLEWVSS 9A ISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGG SLSKSSQGTLVTVSS 210 Anti-HSA sdAb clone EVQLVESGGGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSS 10G ISGSGRDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGG SLSVSSQGTLVTVSS 211 wt anti-HSA EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSS ISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGG SLSRSSQGTLVTVSS 212 Anti-HSA sdAb clone EVQLVESGGGLVQPGNSLRLSCAASGFTFSRFGMSWVRQAPGKGLEWVSS 6CE ISGSGSDTLYAESVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGG SLSRSSQGTLVTVSS 213 Anti-HSA sdAb clone EVQLVESGGGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSS 8HE ISGSGTDTLYAESVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGG SLSRSSQGTLVTVSS 214 Anti-HSA sdAb clone EVQLVESGGGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSS 10GE ISGSGRDTLYAESVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGG SLSVSSQGTLVTVSS 215 wt anti-HSA CDR1 GFTFSSFGMS 216 wt anti-HSA CDR2 SISGSGSDTLYADSVK 217 wt anti-HSACDR3 GGSLSR 218 CDR1 variant 1 GFTFSRFGMS 219 CDR1 variant 2 GFTFSKFGMS 220 CDR1 variant 3 GFTYSSFGMS 221 CDR2 variant 1 SISGSGADTLYADSLK 222 CDR2 variant 2 SISGSGTDTLYADSVK 223 CDR2 variant 3 SISGSGRDTLYADSVK 224 CDR2 variant 4 SISGSGSDTLYAESVK 225 CDR2 variant 5 SISGSGTDTLYAESVK 226 CDR2 variant 6 SISGSGRDTLYAESVK 227 CDR3 variant 1 GGSLSK 228 CDR3 variant 2 GGSLSV

SEQ ID NO: Description AA Sequence 229 Anti-CD3, clone 2B2 EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINWVRQAPGKGLEWVAR IRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HANFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCASSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLVPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCTLWYSNRWVFGGGTKLTVL 230 Anti-CD3, clone 9F2 EVQLVESGGGLVQPGGSLKLSCAASGFEFNKYAMNWVRQAPGKGLEWVAR IRSKYNKYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSFGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYDNRWVFGGGTKLTVL 231 Anti-CD3, clone 5A2 EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSHISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGYVTSGNYPNWVQQKPGQAPRGLIGGTSFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWIFGGGTKLTVL 232 Anti-CD3, clone 6A2 EVQLVESGGGLVQPGGSLKLSCAASGFMFNKYAMNWVRQAPGKGLEWVAR IRSKSNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYISYWATWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSFGAVTSGNYPNWVQQKPGQAPRGLIGGTKLLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNSWVFGGGTKLTVL 233 Anti-CD3, clone 2D2 EVQLVESGGGLVQPGGSLKLSCAASGFTFNTYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYKDSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSPISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVVSGNYPNWVQQKPGQAPRGLIGGTEFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 234 Anti-CD3, clone 3F2 EVQLVESGGGLVQPGGSLKLSCAASGFTYNKYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADEVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSPISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSKGAVTSGNYPNWVQQKPGQAPRGLIGGTKELAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCTLWYSNRWVFGGGTKLTVL 235 Anti-CD3, clone 1A2 EVQLVESGGGLVQPGGSLKLSCAASGNTFNKYAMNWVRQAPGKGLEWVAR IRSKYNNYETYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HTNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLIGGTYFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 236 Anti-CD3, clone 1C2 EVQLVESGGGLVQPGGSLKLSCAASGFTFNNYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADAVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSQISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTDGNYPNWVQQKPGQAPRGLIGGIKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 237 Anti-CD3, clone 2E4 EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAVNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGESTGAVTSGNYPNWVQQKPGQAPRGLIGGTKILAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 238 Anti-CD3, clone EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYPMNWVRQAPGKGLEWVAR 10E4 IRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKNEDTAVYYCVR HGNFNNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTKGNYPNWVQQKPGQAPRGLIGGTKMLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTKLTVL 239 Anti-CD3, clone 2H2 EVQLVESGGGLVQPGGSLKLSCAASGFTFNGYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADEVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSPISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQFPSL TVSPGGTVTLTCGSSTGAVVSGNYPNWVQQKPGQAPRGLIGGTEFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 240 Anti-CD3, clone 2A4 EVQLVESGGGLVQPGGSLKLSCAASGNTFNKYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGDSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQFPSL TVSPGGTVTLTCGSSTGAVTHGNYPNWVQQKPGQAPRGLIGGTKVLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 241 Anti-CD3, clone EVQLVESGGGLVQPGGSLKLSCAASGFTFNNYAMNWVRQAPGKGLEWVAR 10B2 IRSGYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSYTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFNAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYANRWVFGGGTKLTVL 242 Anti-CD3, clone 1G4 EVQLVESGGGLVQPGGSLKLSCAASGFEFNKYAMNWVRQAPGKGLEWVAR IRSKYNNYETYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSLISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSSGAVTSGNYPNWVQQKPGQAPRGLIGGTKFGAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 243 wt anti-CD3 EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 244 Anti-CD3, clone 2G5 EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYALNWVRQAPGKGLEWVAR IRSKYNNYATEYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSPISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTNFLAPGT PERFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWAFGGGTKLTVL 245 Anti-CD3, clone 8A5 EVQLVESGGGLVQPGGSLKLSCAASGFTFNEYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADDVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSGISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTVGNYPNWVQQKPGQAPRGLIGGTEFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL

SEQ ID NO: Description AA Sequence 246 Linker GGGGSGGGS 247 Histidine tag HHHHHH

CD3 Binding Domain CDR Sequences

SEQ CD3 Binding ID NO: Domain CDR Sequence 248 HC CDR1 variant GNTFNKYAMN 1 249 HC CDR1 variant GFEFNKYAMN 2 250 HC CDR1 variant GFMFNKYAMN 3 251 HC CDR1 variant GFTYNKYAMN 4 252 HC CDR1 variant GFTFNNYAMN 5 253 HC CDR1 variant GFTFNGYAMN 6 254 HC CDR1 variant GFTFNTYAMN 7 255 HC CDR1 variant GFTFNEYAMN 8 256 HC CDR1 variant GFTFNKYPMN 9 257 HC CDR1 variant GFTFNKYAVN 10 258 HC CDR1 variant GFTFNKYAIN 11 259 HC CDR1 variant GFTFNKYALN 12 260 HC CDR2 variant RIRSGYNNYATYYADSVK 1 261 HC CDR2 variant RIRSKSNNYATYYADSVK 2 262 HC CDR2 variant RIRSKYNKYATYYADSVK 3 263 HC CDR2 variant RIRSKYNNYETYYADSVK 4 264 HC CDR2 variant RIRSKYNNYATEYADSVK 5 265 HC CDR2 variant RIRSKYNNYATYYKDSVK 6 266 HC CDR2 variant RIRSKYNNYATYYADEVK 7 267 HC CDR2 variant RIRSKYNNYATYYADAVK 8 268 HC CDR2 variant RIRSKYNNYATYYADQVK 9 269 HC CDR2 variant RIRSKYNNYATYYADDVK 10 270 HC CDR3 variant HANFGNSYISYWAY 1 271 HC CDR3 variant HTNFGNSYISYWAY 2 272 HC CDR3 variant HGNFNNSYISYWAY 3 273 HC CDR3 variant HGNFGDSYISYWAY 4 274 HC CDR3 variant HGNFGNSHISYWAY 5 275 HC CDR3 variant HGNFGNSPISYWAY 6 276 HC CDR3 variant HGNFGNSQISYWAY 7 277 HC CDR3 variant HGNFGNSLISYWAY 8 278 HC CDR3 variant HGNFGNSGISYWAY 9 279 HC CDR3 variant HGNFGNSYISYWAT 10 280 LC CDR1 variant ASSTGAVTSGNYPN 1 281 LC CDR1 variant GESTGAVTSGNYPN 2 282 LC CDR1 variant GSYTGAVTSGNYPN 3 283 LC CDR1 variant GSSFGAVTSGNYPN 4 284 LC CDR1 variant GSSKGAVTSGNYPN 5 285 LC CDR1 variant GSSSGAVTSGNYPN 6 286 LC CDR1 variant GSSTGYVTSGNYPN 7 287 LC CDR1 variant GSSTGAVVSGNYPN 8 288 LC CDR1 variant GSSTGAVTDGNYPN 9 289 LC CDR1 variant GSSTGAVTKGNYPN 10 290 LC CDR1 variant GSSTGAVTHGNYPN 11 291 LC CDR1 variant GSSTGAVTVGNYPN 12 292 LC CDR1 variant GSSTGAVTSGYYPN 13 293 LC CDR2 variant GIKFLAP 1 294 LC CDR2 variant GTEFLAP 2 295 LC CDR2 variant GTYFLAP 3 296 LC CDR2 variant GTSFLAP 4 297 LC CDR2 variant GTNFLAP 5 298 LC CDR2 variant GTKLLAP 6 299 LC CDR2 variant GTKELAP 7 300 LC CDR2 variant GTKILAP 8 301 LC CDR2 variant GTKMLAP 9 302 LC CDR2 variant GTKVLAP 10 303 LC CDR2 variant GTKFNAP 11 304 LC CDR2 variant GTKFGAP 12 305 LC CDR2 variant GTKFLVP 13 306 LC CDR3 variant TLWYSNRWV 1 307 LC CDR3 variant ALWYSNRWV 2 308 LC CDR3 variant VLWYDNRWV 3 309 LC CDR3 variant VLWYANRWV 4 310 LC CDR3 variant VLWYSNSWV 5 311 LC CDR3 variant VLWYSNRWI 6 312 LC CDR3 variant VLWYSNRWA 7

SEQ ID NO: Description Sequence 313 Sortase LPETG

SEQ ID NO: Description AA Sequence 314 Linker GGGGSGGGGSGGGGS 315 Linker GGGGSGGGGSGGGGSGGGGS 316 EGFR-human >tr|Q504U8|Q504U8_HUMAN Receptor protein-tyrosine kinase OS = Homo sapiens OX = 9606 GN = EGFR PE = 1 SV = 1 MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLS LQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIP LENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQGQKCDPSCP NGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRE SDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKC PRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEF KDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDIL KTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNI TSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRG ENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGE PREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTC RAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPS IATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPS GEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIK ELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPF GCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLV KTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQS DVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYM IMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDS NFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNS TVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPGEWLV WKQSCSSTSSTHSAAASLQCPSQVLPPASPEGETVADLQTQ 317 EGFR_Mouse >sp|Q01279|EGFR_MOUSE Epidermal growth factor receptor OS = Mus musculus OX = 10090 GN = Egfr PE = 1 S = 1 MRPSGTARTTLLVLLTALCAAGGALEEKKVCQGTSNRLTQLGTFEDHFLS LQRMYNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIP LENLQIIRGNALYENTYALAILSNYGTNRTGLRELPMRNLQEILIGAVRF SNNPILCNMDTIQWRDIVQNVFMSNMSMDLQSHPSSCPKCDPSCPNGSCW GGGEENCQKLTKIICAQQCSHRCRGRSPSDCCHNQCAAGCTGPRESDCLV CQKFQDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV VTDHGSCVRACGPDYYEVEEDGIRKCKKCDGPCRKVCNGIGIGEFKDTLS INATNIKHFKYCTAISGDLHILPVAFKGDSFTRTPPLDPRELEILKTVKE ITGFLLIQAWPDNWTDLHAFENLEIIRGRTKQHGQFSLAVVGLNITSLGL RSLKEISDGDVIISGNRNLCYANTINWKKLFGTPNQKTKIMNNRAEKDCK AVNHVCNPLCSSEGCWGPEPRDCVSCQNVSRGRECVEKCNILEGEPREFV ENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGIM GENNTLVWKYADANNVCHLCHANCTYGCAGPGLQGCEVWPSGPKIPSIAT GIVGGLLFIVVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEA PNQAHLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELR EATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPYGCL LDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTP QHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVW SYGVTVWELMTFGSKPYDGIPASDISSILEKGERLPQPPICTIDVYMIMV KCWMIDADSRPKFRELILEFSKMARDPQRYLVIQGDERMHLPSPTDSNFY RALMDEEDMEDVVDADEYLIPQQGFFNSPSTSRTPLLSSLSATSNNSTVA CINRNGSCRVKEDAFLQRYSSDPTGAVTEDNIDDAFLPVPEYVNQSVPKR RAGSVQNPVYHNQPLHPAPGRDLHYQNPHSNAVGNPEYLNTAQPTCLSSG FNSPALWIQKGSHQMSLDNPDYQQDFFPKETKPNGIFKGPTAENAEYLRV APPSSEFIGA 318 FGFR_Cynomolgus >tr|A0A2K5WK39|A0A2K5WK39_MACFA Receptor protein- tyrosine kinase OS = Macaca fascicularis OX = 9541 GN = EGFR PE = 3 SV = 1 MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLS LQRMENNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIP LENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRF SNNPALCNVESIQWRDIVSSEFLSNMSMDFQNHLGSCQKCDPSCPNGSCW GAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLV CRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV VTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDTLS INATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKE ITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGL RSLKEISDGDVIISGNKNLCYANTINWKKLFGTSSQKTKIISNRGENSCK ATGQVCHALCSPEGCWGPEPRDCVSCQNVSRGRECVDKCNILEGEPREFV ENSECIQCHPECLPQVMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCARNGPKIPSIATGM VGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPN QALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREA TSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLD YVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQH VKITDFGLAKLLGAFEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY GVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKC WMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRA LMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACI DRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKR RAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNST FDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV APQSSEFIGA

SEQ. ID NO. Name Sequence 319 Exemplary EL1 QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELV TriTAC ATSTRDGNVDYAESVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCN sequence ADLRTAVDLIRANYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTENKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKELVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 320 Exemplary QVQLQESGGGLVQAGDSLRLSCVVSGRTDSWYVMGWERQAPGKDREFV EL104 TriTAC AGVSWSYGNTYYADSVKGRFTASRDNAKNTAYLQMNSLNAEDTAVYYC sequence AARVSREVIPTRWDLYNYWGQGTQVTVSSGGGGSGGGSEVQLVESGGG LVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDT LYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSS QGTLVTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFN KYAINWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSK NTAYLQMNNLKTEDTAVYYCVRHANEGNSYISYWAYWGQGTLVTVSSG GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNY PNWVQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQP EDEAEYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 321 Exemplary QVQLQESGGGSVQPGGSLRVSCVVSRTIISINAMTWYHQAPGKRRELV EL106 TriTAC AIITSGGETNYADSVKGRFTISRDNAKNTAYLQMNNLKPEDTGVYYCN sequence VVPPLGSWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQPGNSLRLS CAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSVKGRFT ISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVTVSSGG GGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINWVRQAP GKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQMNNLK TEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGG GGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWVQQKPGQA PRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCTLW YSNRWVFGGGTKLTVLHHHHHH** 322 Exemplary QVQLQESGGGRVQAGGSLRLSCSASARTLRLYAVGWFRQAPGKEREFV EL113 TriTAC AGIGRSERTYYTDSVKGRFTLSRDNAKNTVFLEMNDLEPEDTAVYFCA sequence LTFQTTDMVDVPTTQHEYDYWGRGTQVTVSSGGGGSGGGSEVQLVESG GGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGR DTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSV SSQGTLVTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFT FNKYAINWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDD SKNTAYLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVS SGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSG NYPNWVQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 323 Exemplary QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELV EL12 TriTAC ATSTHDGNITYADSVKGRFTISRDNVKNTVYLQMNSLKPEDTAVYYCN sequence ADLRTAVDLIRANYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 324 Exemplary QVQLQESGGGLVQPGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELV EL120 TriTAC ATSTRDGNITYADSVKGRFTISRDNAKDTVYLQMNSLKPEDTAVYYCN sequence ADLRTAVDLIRANYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 325 Exemplary QVQLQESGGGLVQAGGSLTLSCAASGRYQMAWFRQAPEKEREFVGTIS EL133 TriTAC SGDSTWYTNSVKGRFAISRDSARNTVYLQMNDLKPEDTAIYYCAAALY sequence YRDSRRAADYPYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQPGN SLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSV KGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVT VSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINW VRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQ MNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGG GGSGGGGSQTVVTQEPSLTVSPGGTVTLICASSTGAVTSGNYPNWVQQ KPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEY YCTLWYSNRWVFGGGTKLTVLHHHHHH** 326 Exemplary QVQLQESGGGRVQAGESLRLSCSTSTRTLKLYAVGWFRQAPGKERDFV EL138 TriTAC AGIGRSERIYYIDSVKGRFTLSRDNAKNTVFLEMNDLEPEDTAVYFCA sequence ATFQTSDNVGVPTVQHEYDYWGQGTQVTVSSGGGGSGGGSEVQLVESG GGLVQPGNSLRLSCAASGETFSKFGMSWVRQAPGKGLEWVSSISGSGR DTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSV SSQGTLVTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFT FNKYAINWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDD SKNTAYLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVS SGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLICASSTGAVTSG NYPNWVQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 327 Exemplary QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELV EL147 TriTAC ATSTHDGNIDYADSVKGRFTISRDNAKNIVTLQMNSLKPEDTAVYYCN sequence ADLRTAVDLIRANYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTENKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLICASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 328 Exemplary QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELV EL148 TriTAC ATFTRDGNIDYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCN sequence TDLRTAVDLIRANYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLICASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 329 Exemplary QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELV EL15 TriTAC ATSTHDGNITYADSLKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCN sequence ADLRTAVDLIRANYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTENKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 330 Exemplary QVQLQESGGGSVQAGGSLRLSCAASGRYQMAWFRQAPEKEREFVGTIS EL153 TriTAC SGDSTWYTNSLKGRFAISRDSARDTVYLQMNDLKPEDTAVYYCAAALY sequence YRDSRRAADYPYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQPGN SLRLSCAASGFTFSKFGMSWVRQAPGKGLEMVSSISGSGRDTLYADSV KGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVT VSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINW VRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQ MNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGG GGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWVQQ KPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEY YCTLWYSNRWVFGGGTKLTVLHHHHHH** 331 Exemplary QVQLQESGGGLVQTGGSLRLSCAVSGSIVTINAMTWYRQAPGKRRELV EL16 TriTAC AIITSGGETNYADSVKGRFTISRDNAKNTAHLQMNSLNPEDTGVYYCN sequence VVPPLGSWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQPGNSLRLS CAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSVKGRFT ISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVTVSSGG GGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINWVRQAP GKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQMNNLK TEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGG GGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWVQQKPGQA PRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCTLW YSNRWVFGGGTKLTVLHHHHHH** 332 Exemplary QVQLQESGGGLVQTGGSLRLSCAVSRSIVSIKSMTWYRQAPGKRRELV EL162 TriTAC ALITSGGETNYSDSVKGRFTISRDNAKNTVYLQMNSLKPEDTGVYYCN sequence VVPPLGSWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQPGNSLRLS CAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSVKGRFT ISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVTVSSGG GGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTENKYAINWVRQAP GKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQMNNLK TEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGG GGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWVQQKPGQA PRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCTLW YSNRWVFGGGTKLTVLHHHHHH** 333 Exemplary QVQLQESGGGLVETGGSLRLSCAGSGSTFRHHAMAWFRQTPGKEREFV EL165 TriTAC SAINDHGDRTKYLDSVRGRFTISRDNIDNMVYLQMTDLRPEDTANYSC sequence AAGPLVDYLETTPLVYTYWGHGTQVTVSSGGGGSGGGSEVQLVESGGG LVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDT LYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSS QGTLVTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFN KYAINWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSK NTAYLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSG GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNY PNWVQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQP EDEAEYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 334 Exemplary QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELV EL17 TriTAC ATSTHDGNITYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCN sequence ADLRTAVDLIRANYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 335 Exemplary QVQLQESGGGSVQAGGSLTLSCAASGSIAYIYTMDWYRQAPGKQRELV EL171 TriTAC ATSTHDGNITYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCN sequence ADLRTAVDLIRANYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTENKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 336 Exemplary QVQLQESGGGLVQPGGSLRLSCTASVSIFSVNAVDWYRQSPGKERELV EL172 TriTAC AIMTSDGSTNYGDSVKGRFTISRDNAKNTVYLQMNNLKPEDTAVYYCN sequence TVPPRYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQPGNSLRLSC AASGFTESKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSVKGRFTI SRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVTVSSGGG GSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTENKYAINWVRQAPG KGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQMNNLKT EDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGG GSQTVVTQEPSLTVSPGGTVTLICASSTGAVTSGNYPNWVQQKPGQAP RGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCTLWY SNRWVFGGGTKLTVLHHHHHH** 337 Exemplary QVQLQESGGGLVQPGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELV EL176 TriTAC ATSTRDGNIDYADSVKGRFTISRDSAKNTVYLQMSSLKPEDTAVYYCN sequence ADLRTAVDLIRANYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTESKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTENKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLICASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 338 Exemplary QVQLQESGGGLVQAGGSLTLSCAASGRYQLAWFRQAPEKVREFVGTIS EL178 TriTAC SGDSTWYTNSVKGRFAISRDSARNTVYLQMNDLKPEDTAVYYCAAALY sequence YRDSRRAADYPYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQPGN SLRLSCAASGFTESKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSV KGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVT VSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTENKYAINW VRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQ MNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGG GGSGGGGSQTVVTQEPSLTVSPGGTVTLICASSTGAVTSGNYPNWVQQ KPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEY YCTLWYSNRWVFGGGTKLTVLHHHHHH** 339 Exemplary QVQLQESGGGSVQAGGSLRLSCAASGRYHMAWFRQAPEKEREFVGTIS EL18 TriTAC SGDSTWYTNSVKGRFAISRDSARNTAYLQMNDLKPEDTAVYYCAAALY sequence YGDSRRAADYPYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQPGN SLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSV KGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVT VSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINW VRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQ MNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGG GGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWVQQ KPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEY YCTLWYSNRWVFGGGTKLTVLHHHHHH** 340 Exemplary QVQLQESGGGSVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELV EL187 TriTAC ATSTHDGNITYTDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCN sequence ADLRTAVDLIRANYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 341 Exemplary QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQTPGKQRELV EL27 TriTAC ATSTRDANTDYAGSVKGRFTISRDNAKDTVYLQMNSLKPEDTAVYYCH sequence ADLRTAVDLIRANYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 342 Exemplary QVQLQESGGGLVQAGGSLRLSCAASGRYNMAWFRQAPEKEREFVGTIT EL30 TriTAC SADSTWYTNSVKGRFAITQDSARNTVYLQMNDLKPEDTAVYYCAAALY sequence YGDSRRAADYPYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQPGN SLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSV KGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVT VSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINW VRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQ MNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGG GGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWVQQ KPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEY YCTLWYSNRWVFGGGTKLTVLHHHHHH** 343 Exemplary QVQLQESGGGLVQPGGSLRLSCAASGRYQMAWFRQAPEKEREFVGTIS EL33 TriTAC SGDSTWYTNSVKGRFAISRDSARTTVYLQMNDLKPEDTAVYYCAAALY sequence YRDSWRAADYPYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQPGN SLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSV KGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVT VSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINW VRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQ MNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGG GGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWVQQ KPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEY YCTLWYSNRWVFGGGTKLTVLHHHHHH** 344 Exemplary QVQLQESGGGLVQPGESLRLSCAATGRYHLAWFRQAPEKEREFVGTIT EL35 TriTAC SADSTWYTNSVKGRFAITRDSARNTVYLQMNDLKPEDTAVYYCAAALY sequence YGDSRRAADYPYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQPGN SLRLSCAASGFTFSKFGMSWVRQAPGKGLEMVSSISGSGRDTLYADSV KGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVT VSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINW VRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQ MNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGG GGSGGGGSQTVVTQEPSLTVSPGGIVTLICASSTGAVTSGNYPNWVQQ KPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEY YCTLWYSNRWVFGGGTKLTVLHHHHHH** 345 Exemplary EL4 QVQLQESGGGLVQAGGSLKLSCADSGRSFSNYIMGWFRQAPGKEREFV TriTAC AGLGWSPGNTYYADSVKGRFTISRDNAKNMVYLQMNSLNPEDTAVYYC sequence AARRGDVIYTTPWNYVYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGL VQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTL YADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQ GTLVTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNK YAINWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKN TAYLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGG GGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYP NWVQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPE DEAEYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 346 Exemplary QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELV EL40 TriTAC ATSTHDGNITYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCN sequence ADLRTPVDLIRANYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTENKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 347 Exemplary QVQLQESGGGSVQAGGSLRLSCAAPGRYQMAWFRQAPEKEREFVGTIS EL43 TriTAC SGDSTWYTNSVKGRFAISRDSARNTVYLQMNDLKSEDTAVYYCAAALY sequence YRDSRRAIDYPYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQPGN SLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSV KGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVT VSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINW VRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQ MNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGG GGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWVQQ KPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEY YCTLWYSNRWVFGGGTKLTVLHHHHHH** 348 Exemplary QVQLQESGGGSVQAGGSLRLSCAASGLTFSSYAMAWFRQAPGKQRELV EL44 TriTAC ARITSGGTTDYADSVKGRFTISRDNAKNTMYLQMNSLKPEDTAVYYCA sequence ADLTYRNLLLKLPHYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQ PGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYA DSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGT LVTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYA INWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGG SGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNW VQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDE AEYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 349 Exemplary QVQLQESGGGLVQAGGSLRLSCAASGNIAYIYTMDWYRQAPGKQRELV EL51 TriTAC ATSTHDGSTDYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCN sequence ADLRTPVDLIRANYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTENKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 350 Exemplary QVQLQESGGGLVQPGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELV EL56 TriTAC ATSTWDGNITYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCN sequence ADLRTAVDLIRANYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANEGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 351 Exemplary EL6 QVQLQESGGGLVQAGGSLRLSCAASGSIAYIYTMDWYRQAPGKQRELV TriTAC ATSTHDGNITYADSVKGRFTISRDNAKNTVYLQMSSLKPDDTAVYYCN sequence ADLRTAVDLIRANYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 352 Exemplary QVQLQESGGGLVQAGESLSLSCAASGNDFVITDMHWYRQAPGKQREWV EL64 TriTAC ATITRFATTNYADSVKGRFTISRDNAKNTWYLQMNSLKPDDTAVYYCK sequence AIGLRGVPDVNRQFEVWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLV QPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLY ADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQG TLVTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTENKY AINWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNT AYLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGG GSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPN WVQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPED EAEYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 353 Exemplary QVQLQESGGGLVQAGGSLRLSCAASGAIAYIYGMGWYRQAPGNQRELV EL77 TriTAC AAISSGGSTDYADSVKGRFTISRDNAKNTVYLQMSSLKPEDTAVYYCN sequence ADVRTSRNLVRSDYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 354 Exemplary QVQLQESGGGLVQAGGSLRLSCAASGRYHTAWFRQAPEKEREFVGTIS EL79 TriTAC SGDSTWYTNSVKGRFAISRDSARNTVYLQMNDLKPEDTAVYYCAAALY sequence YGDSRRAGDYPYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQPGN SLRLSCAASGFTFSKFGMSWVRQAPGKGLEMVSSISGSGRDTLYADSV KGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVT VSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINW VRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQ MNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGG GGSGGGGSQTVVTQEPSLTVSPGGTVTLICASSTGAVTSGNYPNWVQQ KPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEY YCTLWYSNRWVFGGGTKLTVLHHHHHH** 355 Exemplary QVQLQESGGGLVQAGGSLRLSCAASGNIAYIYTMNWYRQAPGKQRELV EL83 TriTAC ATSTHAGNITYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCN sequence VDLRTAVDLIRANYWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 356 Exemplary QVQLQESGGGLVQPGGSLRLSCAASGNIAYIYTMGWYRQAPGKQRELV EL88 TriTAC ATSTHDGNSDYADSVKGRFTISRDNAKNTVYLQMNTLKPDDTAVYYCN sequence ADLRTPVDRIRGNFWGQGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTENKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 357 Exemplary EH1 EVQLLESGGGLVQPGGSLTLSCAASGSIAYIYTMDWYRQAPGKQRELV TriTAC ATSTRDGNVDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCN sequence ADLRTAVDLIRANYWGLGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKEGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTENKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLICASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 358 Exemplary EVQLLESGGGLVQPGGSLTLSCAASGRTDSWYVMGWFRQAPGKDREFV EH104 TriTAC AGVSWSYGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC sequence AARVSREVIPTRWDLYNYWGLGTQVTVSSGGGGSGGGSEVQLVESGGG LVQPGNSLRLSCAASGFTESKFGMSWVRQAPGKGLEWVSSISGSGRDT LYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSS QGTLVTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFN KYAINWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSK NTAYLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSG GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNY PNWVQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQP EDEAEYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 359 Exemplary EVQLLESGGGLVQPGGSLTLSCAASARTLRLYAVGWFRQAPGKEREFV EH113 TriTAC AGIGRSERTYYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA sequence LTFQTTDMVDVPTTQHEYDYWGLGTQVTVSSGGGGSGGGSEVQLVESG GGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGR DTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSV SSQGTLVTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFT FNKYAINWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDD SKNTAYLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVS SGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSG NYPNWVQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGV QPEDEAEYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 360 Exemplary EVQLLESGGGLVQPGGSLTLSCAASGSIVTINAMTWYRQAPGKRRELV EH16 TriTAC AIITSGGETNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCN sequence VVPPLGSWGLGTQVTVSSGGGGSGGGSEVQLVESGGGLVQPGNSLRLS CAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSVKGRFT ISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVTVSSGG GGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINWVRQAP GKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQMNNLK TEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGG GGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWVQQKPGQA PRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCTLW YSNRWVFGGGTKLTVLHHHHHH** 361 Exemplary EVQLLESGGGLVQPGGSLTLSCAASGRYHMAWFRQAPGKEREFVGTIS EH18 TriTAC SGDSTWYTNSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAALY sequence YGDSRRAADYPYWGLGTQVTVSSGGGGSGGGSEVQLVESGGGLVQPGN SLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSV KGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVT VSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINW VRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQ MNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGG GGSGGGGSQTVVTQEPSLTVSPGGIVTLICASSTGAVTSGNYPNWVQQ KPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEY YCTLWYSNRWVFGGGTKLTVLHHHHHH** 362 Exemplary EVQLLESGGGLVQPGGSLTLSCAASGSTFRHHAMAWFRQTPGKEREFV EH38 TriTAC SAINDHGDRTKYLDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC sequence AAGPLVDYLETTPLVYTYWGLGTQVTVSSGGGGSGGGSEVQLVESGGG LVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDT LYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSS QGTLVTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFN KYAINWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSK NTAYLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSG GGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNY PNWVQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQP EDEAEYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 363 Exemplary EH4 EVQLLESGGGLVQPGGSLTLSCAASGRSFSNYIMGWFRQAPGKEREFV TriTAC AGLGWSPGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC sequence AARRGDVIYTTPWNYVYWGLGTQVTVSSGGGGSGGGSEVQLVESGGGL VQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTL YADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQ GTLVTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNK YAINWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKN TAYLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGG GGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYP NWVQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPE DEAEYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 364 Exemplary EVQLLESGGGLVQPGGSLTLSCAASGLIFSSYAMAWFRQAPGKQRELV EH44 TriTAC ARITSGGITDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA sequence ADLTYRNLLLKLPHYWGLGTQVTVSSGGGGSGGGSEVQLVESGGGLVQ PGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYA DSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGT LVTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYA INWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGG SGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNW VQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDE AEYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 365 Exemplary EVQLLESGGGLVQPGGSLTLSCAASVSIFSVNAVDWYRQSPGKERELV EH60 TriTAC AIMTSDGSTNYDDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCN sequence TVPPRYWGLGTQVTVSSGGGGSGGGSEVQLVESGGGLVQPGNSLRLSC AASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSVKGRFTI SRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVTVSSGGG GSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINWVRQAPG KGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQMNNLKT EDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGG GSQTVVTQEPSLTVSPGGTVTLICASSTGAVTSGNYPNWVQQKPGQAP RGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCTLWY SNRWVFGGGTKLTVLHHHHHH** 366 Exemplary EVQLLESGGGLVQPGGSLTLSCAASGNDFVITDMHWYRQAPGKQREWV EH64 TriTAC ATITRFATTNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCK sequence AIGLRGVPDVNRQFEVWGLGTQVTVSSGGGGSGGGSEVQLVESGGGLV QPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLY ADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQG TLVTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGETFNKY AINWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNT AYLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGG GSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPN WVQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPED EAEYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 367 Exemplary EVQLLESGGGLVQPGGSLTLSCAASGAIAYIYGMGWYRQAPGKQRELV EH77 TriTAC AAISSGGSTDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCN sequence ADVRTSRNLVRSDYWGLGTQVTVSSGGGGSGGGSEVQLVESGGGLVQP GNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYAD SVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTL VTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTENKYAI NWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGS GGGGSGGGGSQTVVTQEPSLTVSPGGTVTLICASSTGAVTSGNYPNWV QQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEA EYYCTLWYSNRWVFGGGTKLTVLHHHHHH** 

1-68. (canceled)
 69. An EGFR binding protein comprising: (a) a complementarity determining region 1 (CDR1), wherein the CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 50-98; (b) a complementarity determining region 2 (CDR2), wherein the CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 99-147; and (c) a complementarity determining region 3 (CDR3), wherein the CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 148-196.
 70. The EGFR binding protein of claim 69, wherein the CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 51, 53, 62, 70, 76, 89, 90 and
 94. 71. The EGFR binding protein of claim 69, wherein the CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 100, 102, 111, 119, 125, 138, 139 and
 143. 72. The EGFR binding protein of claim 69, wherein the CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 149, 151, 160, 168, 174, 187, 188 and
 192. 73. The EGFR binding protein of claim 69, wherein the CDR1 comprises an amino acid sequence of SEQ ID No. 76, wherein the CDR2 comprises an amino acid sequence of SEQ ID No. 125, and wherein the CDR3 comprises an amino acid sequence of SEQ ID No.
 174. 74. The EGFR binding protein of claim 69, wherein the CDR1 comprises an amino acid sequence of SEQ ID No. 62, wherein the CDR2 comprises an amino acid sequence of SEQ ID No. 111, and wherein the CDR3 comprises an amino acid sequence of SEQ ID No.
 160. 75. The EGFR binding protein of claim 69, wherein the CDR1 comprises an amino acid sequence of SEQ ID No. 70, wherein the CDR2 comprises an amino acid sequence of SEQ ID No. 119, and wherein the CDR3 comprises an amino acid sequence of SEQ ID No.
 168. 76. The EGFR binding protein of claim 69, wherein the CDR1 comprises an amino acid sequence of SEQ ID No. 51, wherein the CDR2 comprises an amino acid sequence of SEQ ID No. 100, and wherein the CDR3 comprises an amino acid sequence of SEQ ID No.
 149. 77. The EGFR binding protein of claim 69, wherein the CDR1 comprises an amino acid sequence of SEQ ID No. 53, wherein the CDR2 comprises an amino acid sequence of SEQ ID No. 102, and wherein the CDR3 comprises an amino acid sequence of SEQ ID No.
 151. 78. The EGFR binding protein of claim 69, wherein the CDR1 comprises an amino acid sequence of SEQ ID No. 94, wherein the CDR2 comprises an amino acid sequence of SEQ ID No. 143, and wherein the CDR3 comprises an amino acid sequence of SEQ ID No.
 192. 79. The EGFR binding protein of claim 69, wherein the CDR1 comprises an amino acid sequence of SEQ ID No. 89, wherein the CDR2 comprises an amino acid sequence of SEQ ID No. 138, and wherein the CDR3 comprises an amino acid sequence of SEQ ID No.
 187. 80. The EGFR binding protein of claim 69, wherein the CDR1 comprises an amino acid sequence of SEQ ID No. 90, wherein the CDR2 comprises an amino acid sequence of SEQ ID No. 139, and wherein the CDR3 comprises an amino acid sequence of SEQ ID No.
 188. 81. The EGFR binding protein of claim 69, wherein the EGFR binding protein comprise an amino acid sequence of SEQ ID Nos.
 2. 82. The EGFR binding protein of claim 69, wherein the EGFR binding protein comprise an amino acid sequence of SEQ ID Nos.
 4. 83. The EGFR binding protein of claim 69, wherein the EGFR binding protein comprise an amino acid sequence of SEQ ID Nos.
 13. 84. The EGFR binding protein of claim 69, wherein the EGFR binding protein comprise an amino acid sequence of SEQ ID Nos.
 21. 85. The EGFR binding protein of claim 69, wherein the EGFR binding protein comprise an amino acid sequence of SEQ ID Nos.
 27. 86. The EGFR binding protein of claim 69, wherein the EGFR binding protein comprise an amino acid sequence of SEQ ID Nos.
 40. 87. The EGFR binding protein of claim 69, wherein the EGFR binding protein comprise an amino acid sequence of SEQ ID Nos.
 41. 88. The EGFR binding protein of claim 69, wherein the EGFR binding protein comprise an amino acid sequence of SEQ ID Nos.
 45. 